

10141236

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:sssptal626kas

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27 Oct 21 EVENTLINE has been reloaded
NEWS 28 Oct 24 BEILSTEIN adds new search fields
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT
NEWS 32 Nov 25 More calculated properties added to REGISTRY
NEWS 33 Dec 02 TIBKAT will be removed from STN
NEWS 34 Dec 04 CSA files on STN
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36 Dec 17 TOXCENTER enhanced with additional content
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 38 Dec 30 ISMEC no longer available
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),

Kamal Saeed

10141236

AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:24:39 ON 14 JAN 2003

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:24:46 ON 14 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 JAN 2003 HIGHEST RN 478909-86-3
DICTIONARY FILE UPDATES: 13 JAN 2003 HIGHEST RN 478909-86-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\Program Files\Stnexp\Queries\09871700.str

L1 STRUCTURE UPLOADED

Kamal Saeed

10141236


=> que L1

L2 QUE L1

=> d

L2 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

=> s l1 full

FULL SEARCH INITIATED 08:26:51 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4424 TO ITERATE

100.0% PROCESSED 4424 ITERATIONS

873 ANSWERS

SEARCH TIME: 00.00.01

L3 873 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

149.35

149.56

FILE 'CAPLUS' ENTERED AT 08:27:07 ON 14 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Jan 2003 VOL 138 ISS 3

FILE LAST UPDATED: 13 Jan 2003 (20030113/ED)

Kamal Saeed

10141236

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3


L4 22 L3

=> d ibib abs hitstr tot

10141236


L4 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:793619 CAPLUS
 DOCUMENT NUMBER: 137:294870
 TITLE: Preparation of prodrugs of
 3-(pyrrol-2-ylmethylenedene)-
 2-indolinones and activity as modulators of protein
 kinases
 INVENTOR(S): Sun, Connie Li; Wei, Chung Chen; Tang, Peng Cho;
 Koenig, Marcel; Zhou, Yong; Vojkovec, Tomas;
 Nematala, Asaad S.
 PATENT ASSIGNEE(S): Sugen, Inc., USA
 SOURCE: PCT Int. Appl., 194 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002081466	A1	20021017	WO 2002-US11001	20020409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: US 2001-282630P P 20010409				
OTHER SOURCE(S): MARPAT 137:294870				
GI				



AB The present invention relates to pyrrole substituted 2-indolinone compds. (shown as 1, e.g. 3-[1-(3,5-dimethyl-1H-pyrrol-2-yl)meth-(2-ylidene)-2-oxo-2,3-dihydroindole-1-carbonyl chloride] and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer (no data). In I,

L4 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 (2-diethylaminoethyl)amide **342642-02-8P**, 5-[5-(3-Chlorophenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
342642-08-4P, 4-Methyl-5-[5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-1H-pyrrole-3-carboxylic acid **342642-09-5P**,
 [(4-Methyl-5-(4-methyl-5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxyl)amino]acetic acid ethyl ester
342642-10-8P, [(4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxyl)amino]acetic acid ethyl ester **342642-11-9P**, [(4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxyl)amino]acetic acid
 RL, PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (protein kinase modulator; prepn. of prodrugs of
 (pyrrol-2-ylmethylenedene)indolinones and activity as modulators of protein kinases)
 RN 342641-96-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-97-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 R1 and R2 are independently H, halo, alkyl, alkylthio, nitro, trihalomethyl, hydroxy, hydroxyalkyl, alkoxy, cyano, aryl, heteroaryl, -C(O)R7 (R7 is alkyl, amino, hydroxy, alkoxy, aryl, heteroaryl, aryloxy, heteroaryloxy, heterocycle, and aminoalkylamino), -NR8R9, NR8C(O)R9, -SO2R8, and -S(O)2NR8R9 (R8 and R9 are independently H, alkyl, aryl and heteroaryl, or R8 and R9 together with the N to which they are attached form a satd. heterocycloamino). R3 is H, alkyl, hydroxyalkyl, aminoalkyl, -C(O)R7, aryl, and heteroaryl; R4 is H, alkyl, -C(O)R7 aryl, and heteroaryl. R5 is H and -COR10 where R10 is alkyl, alkoxy, hydroxy, aryl, aryloxy, heteroaryl, heterocycle, alkylamino, dialkylamino, or -NR11R12 where R11 is H or alkyl, and R12 is aminoalkyl, hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl, alkoxyalkyl, heteroalkyl, or heterocyclylalkyl wherein the alkyl chain in aminoalkyl, heteroalkyl, heteroalkyl, or heterocyclylalkyl is optionally substituted with one or two hydroxy group(s); or R4 and R5 together form - (CH2)4- or - (CH2)nCO(CH2)n- wherein n is 0 to 3, provided that n+m is 3. R6 is: (c) -OR13 wherein R13 is alkyl, trifluoromethyl, carboxyalkyl, aminoalkyl, phosphonoalkyl, sulfoalkyl, hydroxyalkyl, alkoxyalkyl, aryl, heteroaryl, heteroalkyl, heterocyclyl, monosaccharides and heterocyclylalkyl wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonoalkyl, sulfoalkyl, heteroalkyl, heterocyclylalkyl, hydroxyalkyl, or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two C atoms in said alkyl chain are optionally replaced by O, -NR14- (R14 is H or alkyl), -S-, or -SO2-; or, (d) -NR15R16 where R15 and R16 are independently H, alkyl, carboxyalkyl, alkoxyalkyl, aminoalkyl, phosphonoalkyl, sulfoalkyl, hydroxyalkyl, aryl, heteroaryl, heteroalkyl, and heterocyclylalkyl; wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonoalkyl, heteroalkyl, heterocyclylalkyl, hydroxyalkyl, or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two C atoms in the alkyl chain are optionally replaced by O, -NR17- (R17 is H or alkyl), -S-, or -SO2-; or R15 and R16 together with


the N atom to which they are attached form satd. or unsatd. heterocycloamino. Although the methods of prepn. are not claimed, >80 example preps. are included, both of 1 and the unprotected version of I in which the C(O)R6 group has been replaced by H.

IT **342641-96-7P**, 5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-97-8P**,


5-[5-(3-Chlorophenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-98-9P**, 2,4-Dimethyl-5-[2-oxo-5-(pyridin-3-ylsulfamoyl)-1,2-dihydroindol-3-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342642-00-6P**,

3-[3,5-Dimethyl-4-(4-methylpiperazine-1-carboxyl)-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid phenylamide **342642-01-7P**, 5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid

L4 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 342641-98-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-[(3-pyridinylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342642-00-6 CAPLUS
 CN Piperazine,
 1-[[5-[[1,2-dihydro-2-oxo-5-[(phenylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI)
 (CA INDEX NAME)


10141236

L4 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 342642-01-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[5-(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342642-02-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[3-(chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342642-08-4 CAPLUS


CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-

L4 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)


RN 342642-09-5 CAPLUS

CN Glycine, N-[[5-[[1,2-dihydro-4-methyl-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 342642-10-8 CAPLUS

CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-11-9 CAPLUS

CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:676011 CAPLUS
 DOCUMENT NUMBER: 137:216867
 TITLE: CDK-1 inhibitor arylideneoxindoles
 INVENTOR(S): Riou, Jean-Francois; Maratrat, Michel; Grondard, Lucile; Thompson, Fabienne; Petitgenet, Odile; Mailliet, Patrick; Lavayre, Jacques
 PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002068411	A1	20020906	WO 2002-FR681	20020225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2821358	A1	20020830	FR 2001-2624	20010227
PRIORITY APPLN. INFO.:		FR 2001-2624		A 20010227
OTHER SOURCE(S):		MARPAT 137:216867		
GI				



AB Arylideneoxindoles I [R = 3-pyridinyl, 5-pyrimidinyl, alkylcarbonyl, acylamino, halogen, CO2H, alkoxycarbonyl, SO2NH2, NO2, CF3; Ar = (un)substituted 5-imidazolyl, 2-pyrrolyl, 2-furyl, 2-thiazolyl] were prepd. as CDK-1 inhibitors in the treatment of cancers. Thus, 5-(3-pyridinyl)-2-indolinone was treated with 4-imidazolecarboxaldehyde to give I [R = 3-pyridinyl, Ar = 4-imidazolyl] which had an IC50 for CDK-1 inhibition of 0.3 nM.

IT 454234-27-6P 454234-36-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of arylideneoxindoles as CDK-1 inhibitors in treatment of cancer)


RN 454234-27-6 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-imidazol-4-ylmethylene)-2-oxo- (9CI) (CA INDEX NAME)


Kamal Saeed

10141236

L4 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 454234-36-7 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:906590 CAPLUS
 DOCUMENT NUMBER: 136:226315
 TITLE: A prodrug approach to the design of cRaf1 kinase inhibitors with improved cellular activity
 AUTHOR(S): Wood, Edgar; Crosby, Renae M.; Dickerson, Scott; Frye,

CORPORATE SOURCE: GlaxoSmithKline, Research Triangle Park, NC, 27709, USA

SOURCE: Anti-Cancer Drug Design (2001), 16(1), 1-6
 CODEN: ACDEEA; ISSN: 0266-9536

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Earlier we reported potent cRaf1 kinase inhibitors with a key acidic phenol pharmacophore that had, at best, adequate cellular efficacy. To improve the cellular potency, phenol isosteres and prodrugs were investigated. Many phenol isosteres were synthesized and tested, but failed to provide adequate enzyme potency. A prodrug approach resulted

in a 2- to 17-fold improvement over the parent compd. in cell-based efficacy.

IT 402936-58-7 402936-59-8 402936-62-3


RL PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prodrug approach to design of cRaf1 kinase inhibitors with improved cellular activity)

RN 402936-58-7 CAPLUS

CN Carbamic acid, diethyl-,


4-[[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,6-dibromophenyl ester (9CI) (CA INDEX NAME)




RN 402936-59-8 CAPLUS

CN Carbamic acid, diethyl-, 2,6-dibromo-4-[[5-[[2-(dimethylamino)ethyl]amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]phenyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 402936-62-3 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 402936-63-4 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-N-[2-(dimethylamino)ethyl]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:904107 CAPLUS

DOCUMENT NUMBER: 136:37505

TITLE: Preparation of 3-(2-indolylmethylene)-2-indolinones as protein kinase/phosphatase inhibitors for treatment

of

proliferative diseases
 Tang, Peng Cho; Harris, G. Davis; Li, Xiaoyuan
 Sugen, Inc., USA
 PCT Int. Appl., 199 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094312	A2	20011213	WO 2001-US17961	20010604
WO 2001094312	A3	20020808		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002052369 A1 20020502 US 2001-871700 20010604


PRIORITY APPLN. INFO.: US 2000-209162P P 20000602

OTHER SOURCE(S): MARPAT 136:37505

GI



I



II

Kamal Saeed

L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)

AB Title compds. I [wherein R4-R6 and R8-R10 = H; R1, R2, and R3 = independently H, halo, carboxylic acid, trihalomethyl, or (un)substituted ester, amide, alkyl, alkoxy, or (hetero)aryl; R7 = (un)substituted alkyl or alkoxy; or pharmaceutically acceptable salt thereof] were prepd. as modulators of the activity of protein kinases (PKs) and phosphatases.

For example, 5-bromo-2-oxindole was coupled with 5-(3-diethylaminopropyl)-1H-indole-2-carbaldehyde (prepn. given) in the presence of piperidine in EtOH

to afford I, which inhibited GST-FLK-1, EGF receptor kinase, and PDGF with IC50 values of 0.03 .mu.M, 2.87 .mu.M, and 0.38 .mu.M, resp. I are useful in treating disorders related to abnormal PK activity, such as blood vessel proliferative disorders, mesangial cell proliferative disorders, fibrotic disorders, cancer, diabetes, autoimmune disorders, hyperproliferation disorders, restenosis, fibrosis, psoriasis, von Hippel-Lindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis,


inflammatory disorders, immunol. disorders, and cardiovascular disorders (no data). Combinatorial libraries comprising at least five indolinone compds., formed by reacting oxindoles with aldehydes, are also claimed.

IT 258830-88-5P

RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent) (prepn. of (indolylmethylene)indolinones as protein kinase/phosphatase inhibitors for treatment of proliferative diseases)

RN 258830-88-5 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




IT 258830-79-4P 258830-86-3P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses) (prepn. of (indolylmethylene)indolinones as protein kinase/phosphatase inhibitors for treatment of proliferative diseases)

RN 258830-79-4 CAPLUS


CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-N-methyl-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 380242-45-5 CAPLUS

CN Piperazine, 1-[[3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 380242-46-6 CAPLUS

CN Pyrrolidine, 1-[[3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 380242-47-7 CAPLUS


CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N-(2-methoxyethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-48-8 CAPLUS


CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258830-86-3 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-3-[(2-methyl-1H-indol-3-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




IT 258830-66-9P 380242-44-4P 380242-45-5P

380242-46-6P 380242-47-7P 380242-48-8P 380242-49-9P 380242-50-2P 380242-51-3P 380242-52-4P 380242-53-5P 380242-54-6P 380242-55-7P 380242-56-8P 380242-57-9P 380242-58-0P 380242-59-1P 380242-60-4P RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses) (prepn. of (indolylmethylene)indolinones as protein kinase/phosphatase inhibitors for treatment of proliferative diseases)

RN 258830-66-9 CAPLUS


CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-44-4 CAPLUS


CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 380242-49-9 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N-(2-methoxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-50-2 CAPLUS

CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-51-3 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-N-((4-fluorophenyl)methyl)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-52-4 CAPLUS


CN 1H-Indole-5-sulfonamide, 3-[[5-[3-(diethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 380242-53-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((4-methoxy-1H-indol-2-yl)methylene)-2-oxo-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 380242-54-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((4-methoxy-1H-indol-2-yl)methylene)-2-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 380242-55-7 CAPLUS
CN Pyrrolidine, 1-[[2,3-dihydro-3-((4-methoxy-1H-indol-2-yl)methylene)-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 380242-56-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((4-methoxy-1H-indol-2-yl)methylene)-2-oxo-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




IT 380242-01-3P
RL CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of (indolylmethylene)indolinones as protein kinase/phosphatase inhibitors for treatment of proliferative diseases)
RN 380242-01-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((4-methoxy-1H-indol-2-yl)methylene)-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




IT 181223-16-5P 203988-69-6P 215543-45-6P
258830-80-7P 258830-85-2P 258830-87-4P
258830-90-9P 258830-91-0P 380241-51-0P
380241-53-2P 380241-54-3P 380241-56-5P
380241-59-8P 380241-61-2P 380241-65-6P
380241-68-9P 380241-71-4P 380241-74-7P
380241-78-1P 380241-82-7P 380241-84-9P
380241-86-1P 380241-88-3P 380241-90-7P
380241-91-0P 380241-92-9P 380241-93-0P
380241-94-1P 380241-95-2P 380241-96-3P
380241-97-4P 380241-98-5P 380241-99-6P
380242-00-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (indolylmethylene)indolinones as protein kinase/phosphatase inhibitors for treatment of proliferative diseases)
RN 181223-16-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((4-methoxy-1H-indol-2-yl)methylene)-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 380242-57-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((4-methoxy-1H-indol-2-yl)methylene)-N-(2-methoxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 380242-58-0 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-2,3-dihydro-3-((4-methoxy-1H-indol-2-yl)methylene)-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-59-1 CAPLUS
CN 1H-Indole-5-sulfonamide, N-((4-fluorophenyl)methyl)-2,3-dihydro-3-((4-methoxy-1H-indol-2-yl)methylene)-2-oxo- (9CI) (CA INDEX NAME)




RN 380242-60-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((4-methoxy-1H-indol-2-yl)methylene)-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203988-69-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((4-methoxy-1H-indol-2-yl)methylene)-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 215543-45-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((4-methoxy-1H-indol-2-yl)methylene)-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 258830-80-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((4-methoxy-1H-indol-2-yl)methylene)-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 258830-85-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((4-methoxy-1H-indol-2-yl)methylene)-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 258830-87-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((1H-indol-5-yl)methylene)-2-oxo- (9CI) (CA INDEX NAME)



RN 258830-90-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((1H-indol-3-yl)methylene)-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 258830-91-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((2-methyl-1H-indol-3-yl)methylene)-2-oxo- (9CI) (CA INDEX NAME)




RN 380241-51-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-((5-((2-(1-pyrrolidinyl)ethoxy)-1H-indol-2-yl)methylene)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
pyrrolidinyl)ethoxy]-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 380241-61-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-N-phenyl-3-((5-((2-(1-pyrrolidinyl)ethoxy)-1H-indol-2-yl)methylene)- (9CI) (CA INDEX NAME)



RN 380241-65-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-N-3-pyridinyl-3-((5-((2-(1-pyrrolidinyl)ethoxy)-1H-indol-2-yl)methylene)- (9CI) (CA INDEX NAME)




RN 380241-68-9 CAPLUS
CN 1H-Indole, 1-((2,3-dihydro-2-oxo-3-((5-((2-(1-pyrrolidinyl)ethoxy)-1H-indol-2-yl)methylene)-1H-indol-5-yl)sulfonyl)-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 380241-71-4 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-2,3-dihydro-2-oxo-3-((5-((2-(1-pyrrolidinyl)ethoxy)-1H-indol-2-yl)methylene)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 380241-53-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((5-((2-(4-morpholinyl)ethoxy)-1H-indol-2-yl)methylene)-2-oxo- (9CI) (CA INDEX NAME)



RN 380241-54-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-((5-((2-(1-pyrrolidinyl)ethoxy)-1H-indol-2-yl)methylene)- (9CI) (CA INDEX NAME)




RN 380241-56-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-((5-((2-(1-pyrrolidinyl)ethoxy)-1H-indol-2-yl)methylene)- (9CI) (CA INDEX NAME)



RN 380241-59-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-(1-methylethyl)-2-oxo-3-((5-((2-(1-pyrrolidinyl)ethoxy)-1H-indol-2-yl)methylene)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




PAGE 1-A


PAGE 1-B

Cl

RN 380241-74-7 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-2,3-dihydro-N-methyl-2-oxo-3-((5-((2-(1-pyrrolidinyl)ethoxy)-1H-indol-2-yl)methylene)- (9CI) (CA INDEX NAME)



RN 380241-78-1 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(4-chloro-2-fluorophenyl)-2,3-dihydro-2-oxo-3-((5-((2-(1-pyrrolidinyl)ethoxy)-1H-indol-2-yl)methylene)- (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 1-B


Cl

RN 380241-82-7 CAPLUS
CN Quinoline, 2,3-dihydro-2-oxo-3-((5-((2-(1-pyrrolidinyl)ethoxy)-1H-indol-2-yl)methylene)- (9CI) (CA INDEX NAME)


Kamal Saeed

10141236


L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 2-yl)methylene]-1H-indol-5-yl)sulfonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 380241-84-9 CAPLUS
CN Isoquinoline, 2-[[2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl)methylene]-1H-indol-5-yl)sulfonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 380241-86-1 CAPLUS
CN 1H-Indole, 5-bromo-1-[[2,3-dihydro-2-oxo-3-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-2-yl)methylene]-1H-indol-5-yl)sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 380241-88-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl)methylene]-2-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 380241-94-1 CAPLUS
CN 1H-Indole, 1-[[2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl)methylene]-2-oxo-1H-indol-5-yl)sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 380241-95-2 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




PAGE 1-A




PAGE 1-B

RN 380241-96-3 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-2,3-dihydro-N-methyl-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 380241-90-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 380241-91-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-(1-methylethyl)-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 380241-92-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl)methylene]-2-oxo-N-phenyl- (9CI) (CA INDEX NAME)




RN 380241-93-0 CAPLUS

L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 380241-97-4 CAPLUS
CN 1H-Indole-5-sulfonamide, N-(4-chloro-2-fluorophenyl)-2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




PAGE 1-A



PAGE 1-B

RN 380241-98-5 CAPLUS
CN Quinoline, 1-[[2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl)methylene]-2-oxo-1H-indol-5-yl)sulfonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 380241-99-6 CAPLUS
CN Isoquinoline, 2-[[2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl)methylene]-2-oxo-1H-indol-5-yl)sulfonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)


Kamal Saeed

10141236

L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 380242-00-2 CAPLUS
CN 1H-Indole, 5-bromo-1-[[2,3-dihydro-3-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-2-yl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:661426 CAPLUS
DOCUMENT NUMBER: 135:226880
TITLE: Synthesis of Pyrrol-2-one derivatives as kinase inhibitors
INVENTOR(S): Tang, Peng Cho; Miller, Todd A.; Li, Xiaoyuan; Zhang, Ruofei; Cui, Jingrong; Huang, Ping; Wei, Chung Chen
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064681	A2	20010907	WO 2001-US6214	20010228
WO 2001064681	A3	20020418		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002042427	A1	20020411	US 2001-794957	20010228
US 6465507	B2	20021015		
EP 1259514	A2	20021127	EP 2001-913094	20010228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2000-185536P	P 20000228
OTHER SOURCE(S):			WO 2001-US6214	W 20010228
MARPAT 135:226880				
G1				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, alkyl, (hetero)arom. ring, (hetero)aliph. ring, etc.; R2-5 = H, alkyl, (hetero)arom. ring, (hetero)aliph. ring; A, B, D, E

= C or N provided that one or two = N and provided that when A, B, D or E = N, no R1 is attached to A, B, D or E; m = 2 - 4; q = 1 - 4] were prepd. Examples include data for over 50 compds. synthesized and over 20 bioassays (data for 4 bioassays provided). For instance, tosylmethyl isocyanide was added to 5,6-dihydro-2H-pyran-2-one (DBU, THF, 0.degree.C, room temp., 2 h.) to give 6,7-dihydro-2H-pyran-2-one [3,4-c]pyrrol-4-one. This intermediate was formulated in the 1-position (DMF, POC13, DCM, room temp., 1 h.) followed by condensation of the 1-formyl deriv. with 2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid N-Me amide to yield II. II had IC50 = 0.005 mM for cdk2/cyclin A and IC50 = 6.64 mM for GST-Flk1.


L4 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)

Compds. II are used to treat cancer, e.g., squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, etc.


IT 358732-63-5P 358732-64-6P 358732-72-6P
358732-73-7P 358732-74-8P 358732-75-9P
358732-88-4P 358732-90-8P 358732-92-0P
358732-94-2P 358732-96-4P 358733-05-8P
358733-11-6P 358733-20-7P 358733-21-8P
358733-26-3P 358733-27-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug; synthesis of Pyrrol-2-one derivatives as kinase inhibitors)

RN 358732-63-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,4-dimethyl-2-oxo-3-[(2,4,6,7-tetrahydro-4-oxopyrano[3,4-c]pyrrol-1-yl)methylene]- (9CI) (CA INDEX NAME)




RN 358732-64-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(2,4,6,7-tetrahydro-4-oxopyrano[3,4-c]pyrrol-1-yl)methylene]- (9CI) (CA INDEX NAME)




RN 358732-72-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(2,4,6,7-tetrahydro-4-oxopyrano[3,4-c]pyrrol-1-yl)methylene]- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 358732-73-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[(2,4,6,7-tetrahydro-4-oxopyrano[3,4-c]pyrrol-1-yl)methylene]- (9CI) (CA INDEX NAME)



RN 358732-74-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-(1-methylethyl)-2-oxo-3-[(2,4,6,7-tetrahydro-4-oxopyrano[3,4-c]pyrrol-1-yl)methylene]- (9CI) (CA INDEX NAME)




RN 358732-75-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(2,4,6,7-tetrahydro-4-oxopyrano[3,4-c]pyrrol-1-yl)methylene]- (9CI) (CA INDEX NAME)




Kamal Saeed

10141236

L4 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 358732-88-4 CAPLUS
 CN 1H-Indole, 1-[[2,3-dihydro-2-oxo-3-[(2,4,6,7-tetrahydro-4-oxopyrano[3,4-c]pyrrol-1-yl)methylene]-1H-indol-5-yl)sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 358732-90-8 CAPLUS
 CN Quinoline, 1-[[2,3-dihydro-2-oxo-3-[(2,4,6,7-tetrahydro-4-oxopyrano[3,4-c]pyrrol-1-yl)methylene]-1H-indol-5-yl)sulfonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 358732-92-0 CAPLUS
 CN Isoquinoline, 2-[[2,3-dihydro-2-oxo-3-[(2,4,6,7-tetrahydro-4-oxopyrano[3,4-c]pyrrol-1-yl)methylene]-1H-indol-5-yl)sulfonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 358733-11-6 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)



RN 358733-20-7 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)




RN 358733-21-8 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)




RN 358733-26-3 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 358732-94-2 CAPLUS
 CN 1H-Indole, 5-bromo-1-[[2,3-dihydro-2-oxo-3-[(2,4,6,7-tetrahydro-4-oxopyrano[3,4-c]pyrrol-1-yl)methylene]-1H-indol-5-yl)sulfonyl]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 358732-96-4 CAPLUS
 CN 1H-Indole-5-sulfonamide, N-[(3-chlorophenyl)methyl]-2,3-dihydro-2-oxo-3-[(2,4,6,7-tetrahydro-4-oxopyrano[3,4-c]pyrrol-1-yl)methylene]- (9CI) (CA INDEX NAME)




RN 358733-05-8 CAPLUS
 CN 1H-Indole-5-sulfonamide, N-[(3-chlorophenyl)methyl]-2,3-dihydro-2-oxo-3-[(2,4,6,7-tetrahydro-4-oxopyrano[3,4-c]pyrrol-1-yl)methylene]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 5-methyl-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)



RN 358733-27-4 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-5-methyl-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)





10141236

L4 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 200161793 CAPLUS
 DOCUMENT NUMBER: 135:195497
 TITLE: Preparation of pyrrole substituted 2-indolinone protein kinase inhibitors for treatment of cancer
 INVENTOR(S): Tang, Peng Cho; Miller, Todd; Li, Xiaoyuan; Sun, Li; Wei, Chung Chen; Shirazian, Shahrzad; Liang, Congxin; Vojtkovsky, Tomas; Nematala, Asaad S.
 PATENT ASSIGNEE(S): Sugen, Inc., USA
 SOURCE: PCT Int. Appl., 225 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060814	A2	20010823	WO 2001-US4813	20010215
WO 2001060814	A3	20020124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002156292	A1	20021024	US 2001-783264	20010215
EP 1255752	A2	20021113	EP 2001-914376	20010215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NO 200200831 A 20021015 NO 2002-3831 20020813				
PRIORITY APPLN. INFO.: US 2000-182710P P 20000215				
US 2000-216422P P 20000706				
US 2000-243532P P 20010227				
WO 2001-US4813 W 20010215				
OTHER SOURCE(S): MARPAT 135:195497				
GI				

L4 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




AB The title compds. (I) [wherein R1 = H, halo, (cyclo)alkyl, (hetero)aryl, heteroalicyclic, OH, alkoxy, acyl, (un)substituted amino or carbamoyl, etc.; R2 = H, halo, alkyl, trihalomethyl, OH, alkoxy, CN, (hetero)aryl, (un)substituted amino, acyl(amino), or sulfamoyl, etc.; R3 = H, halo, alkyl, trihalomethyl, OH, alkoxy, (hetero)aryl, (un)substituted acyl, (acyl)amino, sulfamoyl, or alkylsulfonyle, etc.; R4 = H, halo, alkyl, OH, alkoxy, or (un)substituted amino; R5 and R6 = independently H, alkyl, or acyl; R7 = H, alkyl, (hetero)aryl, or acyl, and their pharmaceutically acceptable salts] were prepd. as protein kinase modulators for the treatment of cellular disorders such as cancer. For example, 5-fluoro-1,3-dihydroindol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide to give II (55%). II exhibited comparable activity against Flk-1 and PDGFR.beta. and inhibited PDGF-dependent receptor phosphorylation in cells with an IC50 value of approx. 0.03 .mu.M. In efficacy expts. against various cancers in mice, II was well tolerated at 80 mg/kg/day, even when dosed continuously for more than 100 days.

IT 342642-96-7P 342642-97-8P 342642-98-9P
 342642-00-6P 342642-01-7P 342642-02-8P
 342642-04-0P 342642-08-4P 342642-09-5P
 342642-10-8P 342642-11-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of pyrrole substituted 2-indolinone protein kinase inhibitors by condensation of dihydroindolones with formylpyrroles for treatment of cancer and other diseases)

RN 342641-96-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-

L4 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-97-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(3-chlorophenyl)amino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-98-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-[(3-pyridinylamino)sulfonyl]-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 342642-00-6 CAPLUS
 CN Piperazine, 1-[[5-[[1,2-dihydro-2-oxo-5-[(phenylamino)sulfonyl]-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 342642-01-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 342642-02-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[[3-chlorophenyl]amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-(2-(diethylamino)ethyl)-2,4-dimethyl-, (9CI) (CA INDEX NAME)




RN 342642-04-0 CAPLUS
CN 2H-Indole-1-carboxylic acid, 3-[[[1,2-dihydro-2-oxo-5-[[[phenylamino]sulfonyl]-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-08-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[[1,2-dihydro-5-[[[methylamino]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




L4 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 342642-09-5 CAPLUS
CN Glycine, N-[[5-[[[1,2-dihydro-4-methyl-5-[[[methylamino]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 342642-10-8 CAPLUS
CN Glycine, N-[[5-[[[1,2-dihydro-5-[[[methylamino]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-11-9 CAPLUS
CN Glycine, N-[[5-[[[1,2-dihydro-5-[[[methylamino]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:472477 CAPLUS
DOCUMENT NUMBER: 135:56059
TITLE: Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
INVENTOR(S): Lipson, Ken; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045689	A2	20010628	WO 2000-US35009	20001222
WO 2001045689	A3	20020103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KS, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002010203	A1	20020124	US 2000-741842	20001222
EP 1255536	A2	20021113	EP 2000-991704	20001222
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 1999-171693P	P 19991222
			WO 2000-US35009	W 20001222
OTHER SOURCE(S):	MARPAT 135:56059			
AB	The invention concerns indolinone compds. and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity of c-kit kinase.			
IT	330161-87-0 330161-88-1			
(Biological	RL: BAC (Biological activity or effector, except adverse); BSU			
study, unclassified); THU (Therapeutic use); BIOL (Biological study);				
USES	(Uses)			
(indolinone derivs. for c-kit tyrosine protein kinase function modulation)				
RN 330161-87-0 CAPLUS				
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[[[4,5,6,7-tetrahydro-3H-indol-2-yl]methylene]- (9CI) (CA INDEX NAME)				



Kamal Saeed

10141236


L4 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 330161-88-1 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 2,3-dihydro-2-oxo-3-[[4,5,6,7-tetrahydro-1H-indol-
 2-yl)methylene]- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:396655 CAPLUS
 DOCUMENT NUMBER: 135:19549
 TITLE: Preparation of pyrrole substituted 2-indolinones as
 antitumor agents
 INVENTOR(S): Shenoy, Narmada; Sorasuchart, Waranush
 PATENT ASSIGNEE(S): Sugen, Inc., USA
 SOURCE: PCT Int. Appl., 249 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037820	A2	20010531	WO 2000-US32277	20001122
WO 2001037820	A3	20011213		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1233943 A2 20020828 EP 2000-98228 20001122
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 PRIORITY APPLN. INFO.: US 1999-167544P A1 19991124
 WO 2000-US32277 W 20001122
 OTHER SOURCE(S): MARPAT 135:19549
 G1




AB The title compds. [I; R1 = H, alkyl, alkenyl, etc.; R2 = H, halo, alkyl, etc.; R3-R6 = H, alkyl, trihaloalkyl, etc.; R3 and R4, R4 and R5, R5 and R6 may combine to form a six membered aryl ring, OCH2O, OCH2CH2O; R7 = H,

L4 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 alkyl, cycloalkyl, etc.; R8-R10 = H, alkyl, trihaloalkyl, etc.] were prepd. and formulated. E.g., a multi-step synthesis of I [R1-R7 = H; R8, R10 = Me; R9 = (CH2)2CO2H] which showed 79-86% inhibition of tumor growth of Calu-6 cells in mice at 75 and 100 mg/kg/day, was given. The present invention features formulations of indolinones which compds. are ionizable as free acids or free bases. The formulation is suitable for parenteral or oral administration, wherein the formulation comprises an ionizable substituted indolinone, and a pharmaceutically acceptable carrier therefor. The term "ionizable substituted indolinone" includes pyrrole substituted 2-indolinones I which, in addn. to being otherwise optionally substituted on both the pyrrole and 2-indolinone portions of the compd., are necessarily substituted on the pyrrole moiety with one or more hydrocarbon chains which themselves are substituted with at least one polar group.

IT 251356-27-1P 251356-28-2P 251356-75-9P
 251356-76-0P 251356-77-1P 251356-78-2P
 342641-96-7P 342641-97-8P 342641-98-9P
 342642-00-6P 342642-01-7P 342642-02-8P
 342642-04-0P 342642-08-4P 342642-09-5P
 342642-10-8P 342642-11-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 RN 251356-27-1 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 251356-28-2 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 251356-75-9 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 251356-76-0 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 251356-77-1 CAPLUS
 CN Morpholine, 4-[[3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 251356-78-2 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 342641-96-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Kamal Saeed

10141236

L4 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 342641-97-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-98-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[[[1,2-dihydro-2-oxo-5-[(3-pyridinylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 342642-02-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 342642-04-0 CAPLUS
 CN 2H-Isoindole-1-carboxylic acid, 3-[[[1,2-dihydro-2-oxo-5-[(phenylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-08-4 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 342642-00-6 CAPLUS
 CN Piperazine,
 1-[[5-[[[1,2-dihydro-2-oxo-5-[(phenylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI)
 (CA INDEX NAME)




RN 342642-01-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[5-[[[1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 342642-09-5 CAPLUS
 CN Glycine, N-[[5-[[[1,2-dihydro-4-methyl-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-10-8 CAPLUS
 CN Glycine, N-[[5-[[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI)
 (CA INDEX NAME)



RN 342642-11-9 CAPLUS
 CN Glycine, N-[[5-[[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:283924 CAPLUS
 DOCUMENT NUMBER: 134:295737
 TITLE: Preparation of 3-aminomethylene-2-indolinones as kinase and cyclin/CDK complex inhibitors
 INVENTOR(S): Roth, Gerald Juergen; Heckel, Armin; Walter, Rainer; Meel Van, Jacobus; Redemann, Norbert; Schnapp, Gisela;
 Tontsch-Grunt, Ulrike; Spevak, Walter
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027080	A2	20010419	WO 2000-EP9847	20001007
WO 2001027080	A3	20011122		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: OH, OM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19949209	A1	20010419	DE 1999-19949209	19991013
EP 1224169	A2	20020724	EP 2000-966136	20001007
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPLN. INFO.: DE 1999-19949209 A 19991013 WO 2000-EP9847 W 20001007				
OTHER SOURCE(S): MARPAT 134:295737				
GI				



AB Title compds. [I; R1 = H or prodrug residue (sic); R2 = OH, (phenyl)alkoxy, (un)esterified P(O)(OH)2, -SO3H, (un)substituted SO2NH2, etc.; R3 = H, (cyclo) alkyl, (un)substituted Ph, etc.; R4 =


L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 (un)substituted Ph, alkoxy, (oxo)cycloalkyleneimino, etc.; R5 = H or alkyl; X = O or S] were prepd. Thus, 5-methoxy-2-indolinone was treated with with PhC(OEt)3/Ac2O and the product aminated by 4-(piperidinomethyl)aniline to give I [R1 = AC, R2 = OMe, R3 = Ph, R4 = 4-(piperidinomethyl)anilino, X = O]. Data for biol. activity of I were given.

IT 334953-45-6P 334953-46-7P 334953-48-9P
 334953-49-0P 334953-51-4P 334953-53-6P
 334953-55-8P 334953-57-0P 334953-59-2P
 334953-61-6P 334953-63-8P 334953-65-0P
 334953-67-2P 334953-69-4P 334953-71-8P
 334953-73-0P 334953-75-2P 334953-79-6P
 334953-85-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of 3-aminomethylene-2-indolinones as kinase and cyclin/CDK complex inhibitors)


RN 334953-45-6 CAPLUS
 CN 1H-indole-5-sulfonamide, 2,3-dihydro-2-oxo-N-phenyl-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 334953-46-7 CAPLUS
 CN 1H-indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-N-phenyl-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 334953-48-9 CAPLUS
 CN 1H-indole-5-sulfonamide, N-butyl-2,3-dihydro-N-methyl-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 334953-49-0 CAPLUS
 CN 1H-indole-5-sulfonamide, 3-[[[4-[[2-(dimethylamino)ethyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-N-phenyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 334953-51-4 CAPLUS
 CN 1H-indole-5-sulfonamide, 3-[[[4-[[dimethylamino]methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-N-phenyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 334953-53-6 CAPLUS
 CN 1H-indole-5-sulfonamide, 2,3-dihydro-3-[[[1-methyl-4-(piperidinyl)amino]phenylmethylene]-2-oxo-N-phenyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10141236

L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 334953-55-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-N-phenyl-3-phenyl(phenylamino)methylene-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 334953-57-0 CAPLUS
CN Acetamide, N-[4-[[[2]-[1,2-dihydro-2-oxo-5-[(phenylamino)sulfonyl]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 334953-59-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[[3-[(dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-N-phenyl-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 334953-67-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[[4-(4-methyl-1-piperazinyl)phenyl]amino]phenylmethylene]-2-oxo-N-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 334953-69-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[[4-(4-morpholinyl)phenyl]amino]phenylmethylene]-2-oxo-N-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 334953-71-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[[4-[[[4-methylphenyl]sulfonyl]amino]phenyl]amino]phenylmethylene]-2-oxo-N-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 334953-61-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[[4-[[[methyl(phenylmethyl)amino]methyl]phenyl]amino]phenylmethylene]-2-oxo-N-phenyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 334953-63-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-N-phenyl-3-phenyl[[4-[[[1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]amino]methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 334953-65-0 CAPLUS
CN Acetamide, N-[4-[[[2]-[1,2-dihydro-2-oxo-5-[(phenylamino)sulfonyl]-3H-indol-3-ylidene]phenylmethyl]amino]phenyl]-N-methyl-, (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 334953-73-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[[4-[[[dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-N-3-pyridinyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 334953-75-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[[4-[[[dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-N-(3-nitrophenyl)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 334953-79-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-N-3-pyridinyl-, (3Z)- (9CI) (CA INDEX NAME)

Kamal Saeed


10141236

L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
Double bond geometry as shown.




RN 334953-85-4 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[[[4-[(dimethylamino)methyl]phenyl]amino]phenyl
methylene]-2,3-dihydro-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 334953-98-9 334953-99-0 334954-00-6
334954-01-7 334954-02-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of 3-aminomethylene-2-indolinones as kinase and cyclin/CDK
complex inhibitors)
RN 334953-98-9 CAPLUS
CN 1H-Indole-5-sulfonamide,
1-acetyl-3-(ethoxyphenylmethylene)-2,3-dihydro-2-
oxo-N-phenyl- (9CI) (CA INDEX NAME)




RN 334953-99-0 CAPLUS
CN 1H-Indole-5-sulfonamide,
1-acetyl-3-(ethoxyphenylmethylene)-2,3-dihydro-N-
methyl-2-oxo-N-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




IT 334953-94-5P 334953-95-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of 3-aminomethylene-2-indolinones as kinase and cyclin/CDK
complex inhibitors)
RN 334953-94-5 CAPLUS
CN Acetamide,
N-[[[(3Z)-3-[[[4-[(dimethylamino)methyl]phenyl]amino]phenylmethy
lene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 334953-95-6 CAPLUS
CN Acetamide, N-[[[3-(ethoxyphenylmethylene)-2,3-dihydro-2-oxo-1H-indol-5-
yl)sulfonyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 334954-00-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 1-acetyl-N-butyl-3-(ethoxyphenylmethylene)-2,3-
dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 334954-01-7 CAPLUS
CN 1H-Indole-5-sulfonamide,
1-acetyl-3-(ethoxyphenylmethylene)-2,3-dihydro-2-
oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 334954-02-8 CAPLUS
CN 1H-Indole-5-sulfonamide,
1-acetyl-3-(ethoxyphenylmethylene)-2,3-dihydro-N-
(3-nitrophenyl)-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 2001:215821 CAPLUS
DOCUMENT NUMBER: 134:232275
TITLE: SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling
AUTHOR(S): Blake, Robert A.; Broome, Martin A.; Liu, Xiangdong; Wu, Jianming; Gishizky, Mikhail; Sun, Li; Courtneidge, Sara A.
CORPORATE SOURCE: Sugen Inc., South San Francisco, CA, 94080, USA
SOURCE: Molecular and Cellular Biology (2000), 20(23), 9018-9027
CODEN: MCEBD4; ISSN: 0270-7306
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The use of small-mol. inhibitors to study mol. components of cellular signal transduction pathways provides a means of anal. complementary to currently used techniques, such as antisense, dominant-neg. (interfering) mutants and constitutively activated mutants. The authors have identified and characterized a small-mol. inhibitor, SU6656, which exhibits selectivity for Src and other members of the Src family. A related inhibitor, SU6657, inhibits many kinases, including Src and the platelet-derived growth factor (PDGF) receptor. The use of SU6656 confirmed the authors' previous findings that Src family kinases are required for both Myc induction and DNA synthesis in response to PDGF stimulation of NIH 3T3 fibroblasts. By comparing PDGF-stimulated tyrosine phosphorylation events in untreated and SU6656-treated cells, the authors found that some substrates (for example, c-Cbl, and protein kinase C.delta.) were Src family substrates, whereas others (for example, phospholipase C.gamma.) were not. One protein, the adaptor Shc, was a substrate for both Src family kinases (on tyrosines 239 and 240) and a distinct tyrosine kinase (on tyrosine 317, which is perhaps phosphorylated by the PDGF receptor itself). Microinjection expts. demonstrated that a Shc mol. carrying mutations of tyrosines 239 and 240, in conjunction with an SH2 domain mutation, interfered with PDGF-stimulated DNA synthesis. Deletion of the phosphotyrosine-binding domain also inhibited synthesis. These inhibitions were overcome by heterologous expression of Myc, supporting the hypothesis that Shc functions in the Src pathway. SU6656 should prove a useful addnl. tool for further dissecting the role of Src kinases in this and other signal transduction pathways.
IT 330161-87-0, SU 6656 330161-88-1, SU 6657
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (identification and characterization of small-mol. inhibitor SU6656 in relation to selective Src family kinase inhibitor SU6656 used to probe growth factor signaling)
RN 330161-87-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[[[4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)

10141236

L4 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 330161-88-1 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-
 2-yl)methylene]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR
 THIS
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 2000:622463 CAPLUS
 DOCUMENT NUMBER: 133:217719
 TITLE: 3-(Cyclohexanoheteroarylidenyl)-2-indolinone protein
 tyrosine kinase inhibitors, and their therapeutic use
 INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Blake,
 Robert A.
 PATENT ASSIGNEE(S): Sugan, Inc., USA
 SOURCE: U.S., 61 pp., Cont. -in-part of U.S. Ser. No. 99,842.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6114371	A	20000905	US 1998-190970	19981112
US 6130238	A	20001010	US 1998-99842	19980619
US 2002183370	A1	20021205	US 2001-29946	20011231

PRIORITY APPLN. INFO.	US	1997-50977P	P	19970620
	US	1997-59384P	P	19970919
	US	1998-99842	A2	19980619
	US	1997-50413P	P	19970620
	US	1997-59544P	P	19970919
	US	1998-99721	A1	19980619
	US	2000-482198	A3	20000112


OTHER SOURCE(S): CASREACT 133:217719; MARPAT 133:217719
 AB 3-(Cyclohexano-heteroarylidenyl)-2-indolinone compds., and physiol.
 acceptable salts and prodrugs thereof, are disclosed which are expected
 to modulate the activity of protein tyrosine kinases and therefore to be
 useful in the prevention and treatment of protein tyrosine kinase-related
 cellular disorders (cancer, arthritis, restenosis, etc.).
 IT 215543-90-1 215543-91-2
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
 USES

(Uses)
 (cyclohexanoheteroarylidenyl indolinone protein tyrosine kinase
 inhibitors, and therapeutic use)
 RN 215543-90-1 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-
 tetrahydro-1H-inden-2-yl)methylene]- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 215543-91-2 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-1H-inden-
 2-yl)methylene]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR
 THIS
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:417312 CAPLUS
 DOCUMENT NUMBER: 133:159618
 TITLE: Identification of Substituted 3-[(4,5,6,7-Tetrahydro-
 1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as
 Growth Factor Receptor Inhibitors for VEGF-R2
 (Flk-1/KDR), FGF-R1, and PDGF-R.beta. Tyrosine
 Kinases
 AUTHOR(S): Sun, Li; Tran, Ngoc; Liang, Congxing; Hubbard, Steve;
 Tang, Flora; Lipson, Kenneth; Schreck, Randall; Zhou,
 Yong; McMahon, Gerald; Tang, Cho
 CORPORATE SOURCE: SUGEN Inc., South San Francisco, CA, 94080-4811, USA
 SOURCE: Journal of Medicinal Chemistry (2000), 43(14),
 2655-2663
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A series of new 3-substituted indolin-2-ones contg. a tetrahydroindole
 moiety was developed as specific inhibitors of receptor tyrosine kinases
 assocd. with VEGF-R, FGF-R, and PDGF-R growth factor receptors. These
 compds. were evaluated for their inhibitory properties toward VEGF-R2
 (Flk-1/KDR), FGF-R1, PDGF-R.beta., p60c-Src, and EGF-R tyrosine kinases
 and their ability to inhibit growth factor-dependent cell proliferation.
 Structure-activity relationships of this new pharmacophore have been
 detd.

at the level of kinase inhibition. Compds. contg. a propionic acid
 moiety at the C-3' position of the tetrahydroindole ring represented the most
 potent indolin-2-ones to inactivate the VEGF, FGF, and PDGF receptor
 kinases. The inhibitory activities of 3-[3-(2-carboxyethyl)-4,5,6,7-
 tetrahydro-1H-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-
 carboxylic acid against VEGF-R2 (Flk-1), 3-[2-[6-(2-methoxyphenyl)-2-oxo-
 1,2-dihydroindol-3-ylidenemethyl]-4,5,6,7-tetrahydro-1H-indol-3-
 yl]propionic acid against FGF-R1, and
 3-[2-(5-bromo-2-oxo-1,2-dihydroindol-
 3-ylidenemethyl)-4,5,6,7-tetrahydro-1H-indol-3-yl]propionic acid (I)
 against PDGF-R.beta. were 4, 80, and 4 nM, resp. However, all of these
 compds. were inactive when tested against the EGF-R tyrosine kinase.
 Compds. 3-[2-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-
 1H-indol-3-yl]propionic acid (II) and I represented the most potent
 inhibitors of these classes to inhibit both biochem. kinase and growth
 factor-dependent cell proliferation for these three targets. In addn.,
 compd. II was co-crystd. with the catalytic domain of FGF-R1 providing
 evidence to explain the structure-activity relation results. This study
 has provided evidence to support the potential of these new tyrosine
 kinase inhibitors for the treatment of angiogenesis and other growth
 factor-related diseases including human cancers.


IT 288144-21-8P 288144-30-9P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological
 study); PREP (Preparation)
 (substituted [(tetrahydroindolyl)methylene]dihydroindolones as growth
 factor receptor inhibitors for VEGF-R2 (Flk-1/KDR) and FGF-R1, and
 PDGF-R.beta. tyrosine kinases and as inhibitors of growth
 factor-dependent cell proliferation)
 RN 288144-21-8 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-

Kamal Saeed

10141236


L4 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 288144-30-9 CAPLUS
CN 1H-Indole-3-propanoic acid,
2-[(Z)-[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-
indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:146877 CAPLUS
DOCUMENT NUMBER: 132:302969
TITLE: The discovery of potent cRaf-1 kinase inhibitors
AUTHOR(S): Lackey, Karen; Cory, Michael; Davis, Ronda; Frye, Stephen V.; Harris, Philip A.; Hunter, Robert N.; Jung, David K.; McDonald, O. Bradley; McNutt, Robert W.; Peel, Michael R.; Rutkowski, Randy D.; Veal, James


M.; Wood, Edgar R.
CORPORATE SOURCE: Glaxo Wellcome, Inc., Research Triangle Park, NC, 27709, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(3), 221-226
CODEN: BMCLES; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of benzylidene-1H-indol-2-one (oxindole) derivs. was synthesized and evaluated as cRaf-1 Kinase inhibitors. The key features of the mols. were the donor/acceptor motif common to kinase inhibitors and a crit. acidic phenol flanked by two substitutions. Diverse 5-position substitutions provided compds. with low nanomolar kinase enzyme inhibition and inhibited the intracellular MAPK pathway.

IT 220904-67-6
RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); BIOL (Biological study) (structure activity relations of oxindole derivs. as cRaf-1 kinase inhibitors)

RN 220904-67-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-2,3-dihydro-N,N-bis(2-hydroxyethyl)-2-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE



L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:117197 CAPLUS
DOCUMENT NUMBER: 132:166123
TITLE: 3-Methylidenyl-2-indolinone modulators of protein kinase
INVENTOR(S): Tang, Peng Cho; Sun, Li; Miller, Todd Anthony; Liang, Congxin; Tran, Ngoc My; Nguyen, Anh Thi; Nematala, Asaad
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 347 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000008202	A2	20000217	WO 1999-US17845	19990804
WO 2000008202	A3	20000518		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, ME, MK, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9954684	A1	20000228	AU 1999-54684	19990804
JP 2002522452	T2	20020723	JP 2000-563824	19990804
US 2002183364	A1	20021205	US 2001-13944	20011213
PRIORITY APPLN. INFO.:				
US 1998-129256 A 19980804				
US 1998-95470P P 19980805				
US 1998-102178P P 19980928				
US 1999-116107P P 19990115				
WO 1999-US17845 W 19990804				
US 1999-407164 A1 19990928				

OTHER SOURCE(S): MARPAT 132:166123
O1

L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




AB The title compds. (I) [wherein A = C or N; Q = substituted Ph, pyrrolyl, or indolyl; R0 = H, alkyl, C(O)R19, or C(O)OR19; R1 = H, (un)substituted alkyl, alkoxy, halo, aryl, (CH2)nOC(O)R19, or C(O)NR19; R2 = H, (cyclo)alkyl, (hetero)aryl, heteroalicyclic, trihalomethyl, alkoxy, halo, sulfamido, C(O)OR19, C(O)R19, NHC(O)OR19, (un)substituted amino, etc.; R3 = H, alkyl, trihalomethyl, alkoxy, aryl(oxy), heteroaryl, heteroalicyclic, OH, halo, sulfamido, C(O)R19, (un)substituted amino, etc.; R4 = H, alkyl, alkoxy, or halo; R19 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; n = 1-4] were prepd. as modulators of the activity of receptor tyrosine kinases (RTKs), non-receptor protein tyrosine kinases (CTKs), and serine/threonine protein kinases (STKs). Examples include over 200 syntheses and data from seventeen bioassays. For instance, II was prepd. by a 3-step sequence involving: (1) cyclization and redn. of 2,4-dinitrophenylacetic acid with SnCl2.2H2O in EtOH to form 6-amino-2-oxindole, (2) amidation with AcCl in CH2Cl2, and (3) condensation of the amide with 3,5-diisopropyl-4-methoxybenzaldehyde. II was tested for HER-2 kinase activity (IC50 = 6.4 .mu.M), cellular proliferation activity as measured by the incorporation of bromodeoxyuridine (BrdU) driven by HER-2 (IC50 = 9.1 .mu.M) or EGF (IC50 = 11 .mu.M), and antitumor activity as measured by growth of SKOV3 ovarian carcinoma cells (IC50 = 2.6 .mu.M) or A431 human epidermoid carcinoma cells (IC50 = 2.2 .mu.M). The invention compds. are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer, diabetes, hepatic cirrhosis, cardiovascular disease, and immunol. disease.

IT 215543-45-6P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (target compd.; as protein kinase modulators for the prevention and treatment of cancer, diabetes, hepatic cirrhosis, cardiovascular disease, and immunol. disease)

Kamal Saeed


10141236

L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 215543-45-6 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(2-methyl-1H-indol-3-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




IT 181223-16-5P 203988-69-6P 258830-06-7P
 258830-07-8P 258830-11-4P 258830-12-5P
 258830-18-1P 258830-21-6P 258830-26-1P
 258830-28-3P 258830-41-0P 258830-43-2P
 258830-45-4P 258830-47-6P 258830-49-8P
 258830-57-8P 258830-59-0P 258830-61-4P
 258830-66-9P 258830-79-4P 258830-80-7P
 258830-85-2P 258830-86-3P 258830-87-4P
 258830-88-5P 258830-90-9P 258830-91-0P
 258831-04-8P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compd.; prepn. of 3-methylidenyl-2-indolinones as protein
 kinase modulators for the prevention and treatment of cancer,
 diabetes, hepatic cirrhosis, cardiovascular disease, and immunol. disease)
 RN 181223-16-5 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-
 (9CI) (CA INDEX NAME)




RN 203988-69-6 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 2,3-dihydro-3-(1H-indol-3-ylmethylene)-N-methyl-2-
 oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 (9CI) (CA INDEX NAME)



RN 258830-12-5 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-18-1 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(1-pyrrolidinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-21-6 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-[3-(dimethylamino)propyl]-2-methyl-, ethyl ester


L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258830-06-7 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid,
 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-morpholinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-07-8 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid,
 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-methyl-1-piperazinyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-11-4 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-4-[3-(4-morpholinyl)propyl]-, ethyl ester


L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 (9CI) (CA INDEX NAME)



RN 258830-26-1 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid,
 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-[3-(dimethylamino)propyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 258830-28-3 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid,
 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-[3-(dimethylamino)propyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 258830-41-0 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 2-[[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 258830-43-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 258830-45-4 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 258830-47-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[[1,2-dihydro-5-[(1-methylethylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 258830-66-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-2-oxo- (9CI) (CA INDEX NAME)



RN 258830-79-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-5-ylmethylene)-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 258830-80-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-5-ylmethylene)-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 258830-85-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-5-ylmethylene)-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 258830-49-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-[(dimethylamino)propyl]-1H-indol-2-yl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 258830-57-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[3-methyl-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 258830-59-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[[3-methyl-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 258830-61-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-3-[[3-methyl-1H-indol-2-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 258830-86-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-3-[[2-methyl-1H-indol-3-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 258830-87-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-5-ylmethylene)-2-oxo- (9CI) (CA INDEX NAME)




RN 258830-88-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-2-ylmethylene)-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 258830-90-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 258830-91-0 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-3-[(2-methyl-1H-indol-3-yl)methylene]-
2-oxo- (9CI) (CA INDEX NAME)




RN 258831-04-8 CAPLUS
CN 1H-Indole-3-propanoic acid, 2-[[1,2-dihydro-5-[[[(1-methylethyl)amino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



I



II

AB The present invention relates to 5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-ylalkanoic acid derivs. (I) [where R1 and R7 = independently H, (cyclo)alkyl, alkenyl, alkynyl, aryl, OH, alkoxy, carboxy, acetyl, (thio)amido, (trihalomethane)sulfonyl, etc.; R2 = H, halo, (cyclo)alkyl, (hetero)aryl, or heterocyclic; R3, R4, R5, R6, R8, R9, R10 = independently H, (cyclo)alkyl, trihaloalkyl, alkenyl, alkynyl, (hetero)aryl(oxy), heterocyclic, OH, alkoxy, SH, alkylthio, arylthio, sulfinyl, sulfonyl, sulfonamido, carbonyl, carboxy, amido, CN, NO2, halo,

(thio)carbonyl, (un)substituted amino, etc.] which modulate the activity of protein kinases and are useful in the prevention and treatment of protein kinase related cellular disorders, such as cancer. Thus, 2,4-dimethyl-5-ethoxycarbonyl-3-(2-ethoxycarbonyl)pyrrole was deprotected using NaOH to form 3-(2-carboxyethyl)-2,4-dimethylpyrrole (100%) and the product C-5 formulated (two methods given for 86% and 90% yield, resp.). Reaction with 2-oxindole in EtOH and pyrrolidine or in

aq. NaOH yielded II (88% and 91%, resp.), which reduced the av. size of C6 human glioma and melanoma tumors s.c. implanted in mice by 80-85%. II, when administered orally, demonstrated notably superior efficacy compared to structurally similar analogs.

IT 251356-27-1P 251356-28-2P 251356-75-9P
251356-76-0P 251356-77-1P 251356-78-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BTOL (Biological study); PREP (Preparation); USES (Uses) (target compd.; prepn. of

5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-ylalkanoic acid protein kinase inhibitors as antitumor agents)


RN 251356-27-1 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1999:764021 CAPLUS
DOCUMENT NUMBER: 132:12257
TITLE: Preparation of pyrrole substituted 2-indolinone protein kinase inhibitors
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 240 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961422	A1	19991202	WO 1999-US12069	19990528
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
TM				
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2314156	AA	19991202	CA 1999-2314156	19990528
AU 9944102	A1	19991213	AU 1999-44102	19990528
EP 1082305	A1	20010314	EP 1999-927120	19990528
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 9910792	A	20020129	BR 1999-10792	19990528
US 6395734	B1	20020528	US 1999-322297	19990528
JP 2002516310	T2	20020604	JP 2000-550828	19990528
NO 200005916	A	20010129	NO 2000-5916	20001122
PRIORITY APPLM. INFO.:			US 1998-87310P	P 19980529
			US 1999-116106P	P 19990115
			WO 1999-US12069	W 19990528
OTHER SOURCE(S):			MARPAT 132:12257	
GI				


L4 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 251356-28-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 251356-75-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 251356-76-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 251356-77-1 CAPLUS
CN Morpholine, 4-[[3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


Kamal Saeed

10141236

L4 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 251356-78-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 1H-Pyrrole-3-propanoic acid, 5-[[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 256657-65-5 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[5-(aminosulfonyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1999:757553 CAPLUS
DOCUMENT NUMBER: 132:137242
TITLE: Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidene]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases
AUTHOR(S): Sun, Li; Tran, Ngoc; Liang, Congxin; Tang, Flora; Rice, Audie; Schreck, Randall; Wultz, Kara; Shawver, Laura K.; McMahon, Gerald; Tang, Cho
CORPORATE SOURCE: SUGEN Inc., South San Francisco, CA, 94080-4811, USA
SOURCE: Journal of Medicinal Chemistry (1999), 42(25), 5120-5130
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Receptor tyrosine kinases (RTKs) were implicated as therapeutic targets for the treatment of human diseases including cancers, inflammatory diseases, cardiovascular diseases including arterial restenosis, and fibrotic diseases of the lung, liver, and kidney. Three classes of 3-substituted 2-indolinones contg. propanoic acid functionality attached to the pyrrole ring at the C-3 position of the core were identified as catalytic inhibitors of the vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) RTKs. Some of the compds. were found to inhibit the tyrosine kinase activity assocd. with isolated vascular endothelial growth factor receptor 2 (VEGF-R2) [fetal liver tyrosine kinase 1 (Flk-1)/kinase insert domain-contg. receptor (KDR)], fibroblast growth factor receptor (FGF-R), and platelet-derived growth factor receptor (PDGF-R) tyrosine kinase with IC50 values at nanomolar level. Thus, SU 5402 [5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrole-3-propanoic acid] showed inhibition against VEGF-R2 (Flk-1/KDR) and FGF-R1 tyrosine kinase activity with IC50 values of 20 and 30 nM, resp., while 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid inhibited the PDGF-R tyrosine kinase activity with IC50 value of 10 nM. Structural models and structure-activity relationship anal. of these compds. for the target receptors are discussed. The cellular activities of these compds. were profiled using cellular proliferation assays as measured by bromodeoxyuridine (BrdU) incorporation. Specific and potent inhibition of cell growth was obsd. for some of these compds. These data provide evidence that these compds. can be used to inhibit the function of these target receptors.
IT 251356-27-1P 256657-65-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. and evaluation of [(dihydrooxindolylidene)methyl]pyrrolepropanoic acid as tyrosine kinase inhibitors)
RN 251356-27-1 CAPLUS

L4 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:166598 CAPLUS
DOCUMENT NUMBER: 130:209599
TITLE: Preparation of benzylidene-1,3-dihydroindol-2-ones as receptor tyrosine kinase inhibitors.
INVENTOR(S): McNutt, Robert Walton, Jr.; Jung, David Kendall; Harris, Philip Anthony; Hunter, Robert Neil, III; Veal, James Marvin; Dickerson, Scott; Lackey, Karen Elizabeth; Peel, Michael Robert
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9910325	A1	19990304	WO 1998-EP4844	19980804
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9891584	A1	19990316	AU 1998-91584	19980804
EP 1003721	A1	20000531	EP 1998-943832	19980804
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2002514228	T2	20020514	JP 1999-513839	19980804
ZA 9807037	A	20000207	ZA 1998-7037	19980805
US 6268391	B1	20010731	US 2000-446586	20000407
PRIORITY APPLM. INFO.:			GB 1997-16557	A 19970806
			WO 1998-EP4844	W 19980804
OTHER SOURCE(S):		MARPAT 130:209599		
GI				



AB Title compds. [I; R1 = H; R1R2 = fused 5-10 membered aryl, heteroaryl,

Kamal Saeed


10141236

L4 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
heterocyclyl; R2, R3 = H, HET, aryl, alipharyl, cyano, NO2, halo, R10, OR10, SR10, SOR10, SO2R10, NR10R11, etc.; R4 = H, halo, NO2, cyano; R5 = H, (substituted) alipharyl; R6, R7 = halo, cyano, NO2, CONR10R11, SONR10R11, NR10R11, OR11; R8 = OH, NHO2R12, NHCOCF3; R10 = H, halo, (substituted) alipharyl, aryl, HET; R11 = H, R10; R12 = H, (substituted) alipharyl, HET; HET = benzofuryl, benzoxazolyl, dioxanyl, dithianyl, dithiazinyl, furyl, imidazolyl, indolyl, indazolyl, morpholinyl, tetrazolyl, pyrrollyl, quinolinyl, triazinyl, tetrahydrofuryl, etc.), were prepd. for treatment of tumor growth, preventing organ transplant rejection, healing chronic wounds, etc. (no data). Thus, 5-(2-methylthiazol-4-yl)-1,3-dihydroindol-2-one hydrochloride (prepn. given) was stirred with 3,5-dibromo-4-hydroxybenzaldehyde in AcOH/aq. HCl to give 644

3-(3,5-dibromo-4-hydroxybenzylidene)-5-(2-methylthiazol-4-yl)-1,3-dihydroindol-2-one.

IT 220904-64-3P 220904-66-5P 220904-67-6P
RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of benzylidene-1,3-dihydroindol-2-ones as receptor tyrosine kinase inhibitors.)


RN 220904-64-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-N-[2-(dimethylamino)ethyl]-2,3-dihydro-N-methyl-2-oxo-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 220904-66-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dichloro-4-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 220904-67-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-2,3-dihydro-N-bis(2-hydroxyethyl)-2-oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:747592 CAPLUS
DOCUMENT NUMBER: 130:3771
TITLE: Preparation of 3-(hetero)arylmethylidene-2-indolinone derivatives as modulators of protein kinase activity for use in treating cancer.
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Shawver, Laura Kay; Hirth, Klaus Peter
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 269 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850356	A1	19981112	WO 1998-US9017	19980507
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9876842	A1	19981127	AU 1998-76842	19980507
EP 984930	A1	20000315	EP 1998-924746	19980507
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2002511852	T2	20020416	JP 1998-548319	19980507
US 6051593	A	20000418	US 1998-99721	19980619
US 6313158	B1	20011106	US 1998-100854	19980619
US 6133305	A	20001017	US 1998-161046	19980925
US 2001056094	A	20011227	US 2000-482198	20000112
US 2001007033	A1	20010705	US 2000-516948	20000301
US 2002026053	A1	20020228	US 2001-916331	20010730
US 2002058661	A1	20020516	US 2001-948106	20010907
US 2002183370	A1	20021205	US 2001-29946	20011231
PRIORITY APPLN. INFO.:			US 1997-45838P	P 19970507
			US 1997-46868P	P 19970508
			US 1997-49324P	P 19970611
			US 1997-50412P	P 19970620
			US 1997-50413P	P 19970620
			US 1997-50977P	P 19970620
			US 1997-59336P	P 19970919
			US 1997-59381P	P 19970919
			US 1997-59384P	P 19970919
			US 1997-59544P	P 19970919
			US 1997-59677P	P 19970919
			US 1997-59971P	P 19970925
			US 1997-60194P	P 19970926
			WO 1998-US9017	W 19980507
			US 1998-100854	A3 19980619
			US 1998-99721	A1 19980619
			US 1998-161046	A3 19980925
			US 2000-482198	A3 20000112
			US 2000-516948	B1 20000301

OTHER SOURCE(S): MARPAT 130:3771

L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



AB Title compds. [I; A1-A4 = C, N; when any of A1-A4 = N, then the corresponding R3-R6 = null; R1 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclicyl, trihalomethylcarbonyl, OH, CO2H, trihalomethylsulfonfyl, etc.; R2 = H, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclicyl, halo; R3-R6 = H, alkyl, trihalomethyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclicyl, OH, SH, alkoxy, aryloxy, amino, phosphonyl, guanidiny, NO2, halo, (isocyanato, etc.; R3R4 or R4R5 or R5R6 = cycloalkyl, aryl, heteroaryl, heteroalicyclicyl, OCH2O, OCH2CH2O; Q = specified (substituted) (hetero)aryl; Z = O, S], were prepd. Thus, 3-(4-imidazolylmethylidenyl)-4,6-dimethyl-2-indolinone inhibited CDK2 with IC50 = <0.78 .mu.M.

IT 204001-78-5 204001-79-6 204001-80-9 204001-81-0 204001-82-1 204001-83-2 204001-84-3 204001-85-4 204001-86-5 204001-87-6 204001-88-7 204001-89-8 204001-90-1 204001-91-2 204001-92-3 204001-93-4 204001-94-5 204001-95-6 204001-96-7 204001-97-8 204001-98-9 204001-99-0 204002-00-6 204002-01-7 204002-02-8 204002-03-9 204002-04-0 204002-05-1 204002-06-2 204002-07-3 215538-89-9 215538-90-2 215538-91-3 215538-92-4 215538-93-5 215538-94-6 215538-95-7 215538-96-8 215538-97-9 215538-98-0 215538-99-1 215539-00-7 215539-01-8 215539-03-0 215539-05-2 215539-07-4 215539-09-6 215539-11-0 215539-13-2 215539-15-4 215539-16-5 215539-17-6 215539-18-7 215539-19-8 215539-20-1 215539-21-2 215539-22-3 215539-23-4 215539-24-5 215539-25-6 215539-77-8 215539-78-9 215539-79-0 215539-80-3 215539-81-4 215539-82-5 215539-83-6 215539-84-7 215539-85-8 215539-86-9 215539-87-0 215539-88-1 215539-89-2 215539-90-5 215539-91-6 215539-92-7 215539-93-8 215539-94-9 215539-95-0 215539-96-1 215539-97-2 215539-98-3 215539-99-4 215540-00-4 215540-01-5 215540-02-6 215540-03-7 215540-04-8 215540-05-9 215540-06-0 215540-59-3 215540-60-6 215540-61-7

Kamal Saeed

10141236

L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


215540-62-9 215540-63-9 215540-64-0
215540-65-1 215540-66-2 215540-67-3
215540-68-4 215540-69-5 215540-70-8
215540-71-9 215540-72-0 215540-73-1
215540-74-2 215540-75-3 215540-76-4
215540-77-5 215540-78-6 215540-79-7
215540-80-0 215540-81-1 215540-82-2
215540-83-3 215540-84-4 215540-85-5
215540-86-6 215540-87-7 215540-88-8
215541-64-3 215541-65-4 215541-66-5
215541-67-6 215541-68-7 215541-69-8
215541-70-1 215541-71-2 215541-72-3
215541-73-4 215541-74-5 215541-75-6
215541-76-7 215541-77-8 215541-78-9
215541-79-0 215541-80-3 215541-81-4
215541-82-5 215541-83-6 215541-84-7
215541-85-8 215541-86-9 215541-87-0
215541-88-1 215541-89-2 215541-90-5
215541-91-6 215541-92-7 215541-93-8
215542-53-3 215542-54-4 215542-55-5
215542-56-6 215542-57-7 215542-58-8
215542-59-9 215542-60-2 215542-61-3
215542-62-4 215542-63-5 215542-64-6
215542-65-7 215542-66-8 215542-67-9
215542-68-0 215542-69-1 215542-70-4
215542-71-5 215542-72-6 215542-73-7
215542-74-8 215542-75-9 215542-76-0
215542-77-1 215542-78-2 215542-79-3
215542-80-6 215542-81-7 215542-82-8
215543-35-4 215543-37-6 215543-39-8
215543-41-2 215543-43-4 215543-44-5
215543-45-6 215543-47-8 215543-48-9
215543-49-0 215543-50-3 215543-51-4
215543-52-5 215543-53-6 215543-54-7
215543-55-8 215543-56-9 215543-57-0
215543-58-1 215543-59-2 215543-60-5
215543-61-6 215543-62-7 215543-63-8
215543-64-9 215543-65-0 215543-66-1
215543-67-2 215543-68-3 215543-69-4
215543-90-1 215543-91-2

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES
(Uses)
(prepn. of 3-(hetero)arylmethylidene-2-indolinone deriva. as
modulators
of protein kinase activity for use in treating cancer)


RN 204001-78-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-ethoxy-2-hydroxyphenyl)methylene]-2,3-
dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN 1H-Indole-5-sulfonamide, 3-[(4-nitrophenyl)methylene]-2,3-
dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-83-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dibromo-2-hydroxyphenyl)methylene]-2,3-
dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 204001-84-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-fluoro-2-hydroxyphenyl)methylene]-2,3-
dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-85-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-bromo-4-hydroxyphenyl)methylene]-2,3-
dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-86-5 CAPLUS


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 204001-79-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dichloro-2-hydroxyphenyl)methylene]-2,3-
dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 204001-80-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(5-chloro-2-hydroxyphenyl)methylene]-2,3-
dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-81-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-(diethylamino)-2-hydroxyphenyl)methylene]-2,3-
dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-82-1 CAPLUS

L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN 1H-Indole-5-sulfonamide, 3-[[4-(1,1-dimethylethyl)phenyl)methylene]-2,3-
dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 204001-87-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(5-bromo-2-thienyl)methylene]-2,3-dihydro-N-
methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-88-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-ethoxy-2-hydroxyphenyl)methylene]-2,3-
dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204001-89-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dichloro-2-hydroxyphenyl)methylene]-2,3-
dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204001-90-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(5-chloro-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204001-91-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-(diethylamino)-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204001-92-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-nitrophenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204001-96-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-(1,1-dimethylethyl)phenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204001-97-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(5-bromo-2-thienyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204001-98-9 CAPLUS
CN Morpholine, 4-[(3-ethoxy-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204001-93-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dibromo-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204001-94-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-fluoro-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204001-95-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-bromo-4-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204001-99-0 CAPLUS
CN Morpholine, 4-[(3-[(3,5-dichloro-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 204002-00-6 CAPLUS
CN Morpholine, 4-[(3-[(5-chloro-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 204002-01-7 CAPLUS
CN Morpholine, 4-[(3-[(4-(diethylamino)-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204002-02-8 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(4-nitrophenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204002-03-9 CAPLUS
CN Morpholine, 4-[[3-[(3,5-dibromo-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204002-04-0 CAPLUS
CN Morpholine, 4-[[3-[(3-fluoro-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Morpholine, 4-[[3-[(5-bromo-2-thienyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 215538-89-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(2-methylphenyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 215538-90-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,4-difluorophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215538-91-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-difluorophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 204002-05-1 CAPLUS
CN Morpholine, 4-[[3-[(3-bromo-4-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204002-06-2 CAPLUS
CN Morpholine, 4-[[3-[(4-(1,1-dimethylethyl)phenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204002-07-3 CAPLUS


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 215538-92-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(3-(trifluoromethyl)phenyl)methylene]- (9CI) (CA INDEX NAME)



RN 215538-93-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-bis(trifluoromethyl)phenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 215538-94-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2-cyanophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215538-95-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,6-difluorophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


Kamal Saeed

10141236


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215538-96-8 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-N-methyl-3-((1-naphthalenyl)methylene)-
2-oxo- (9CI) (CA INDEX NAME)




RN 215538-97-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-((2,4-dichlorophenyl)methylene)-2,3-dihydro-N-
methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215538-98-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-((1,1'-biphenyl)-4-ylmethylene)-2,3-dihydro-N-
methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215539-03-0 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-2-oxo-N-((3-(trifluoromethyl)phenyl)methylene)-3-
[[3-(trifluoromethyl)phenyl)methylene]- (9CI) (CA INDEX NAME)




RN 215539-05-2 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[[3,5-bis(trifluoromethyl)phenyl)methylene]-2,3-
dihydro-2-oxo-N-((4-(trifluoromethyl)phenyl)methylene)- (9CI) (CA INDEX NAME)




RN 215539-07-4 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-((2-cyanophenyl)methylene)-2,3-dihydro-2-oxo-N-
[[4-(trifluoromethyl)phenyl)methylene]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215538-99-1 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-3-((2-methylphenyl)methylene)-2-oxo-N-
[[4-(trifluoromethyl)phenyl)methylene]- (9CI) (CA INDEX NAME)




RN 215539-00-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-((3,4-difluorophenyl)methylene)-2,3-dihydro-2-
oxo-N-((4-(trifluoromethyl)phenyl)methylene)- (9CI) (CA INDEX NAME)




RN 215539-01-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-((3,5-difluorophenyl)methylene)-2,3-dihydro-2-
oxo-N-((4-(trifluoromethyl)phenyl)methylene)- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215539-09-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-((2,6-difluorophenyl)methylene)-2,3-dihydro-2-
oxo-N-((4-(trifluoromethyl)phenyl)methylene)- (9CI) (CA INDEX NAME)




RN 215539-11-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((1-naphthalenyl)methylene)-2-oxo-N-
[[4-(trifluoromethyl)phenyl)methylene]- (9CI) (CA INDEX NAME)




RN 215539-13-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-((2,4-dichlorophenyl)methylene)-2,3-dihydro-2-
oxo-N-((4-(trifluoromethyl)phenyl)methylene)- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215539-15-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-((1,1'-biphenyl)-4-ylmethylene)-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215539-16-5 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(2-methylphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215539-17-6 CAPLUS
CN Morpholine, 4-[[3-[(3,4-difluorophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215539-21-2 CAPLUS
CN Morpholine, 4-[[3-[(2-cyanophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215539-22-3 CAPLUS
CN Morpholine, 4-[[3-[(2,6-difluorophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215539-23-4 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-(1-naphthalenylmethylene)-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215539-18-7 CAPLUS
CN Morpholine, 4-[[3-[(3,5-difluorophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215539-19-8 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-[[3-(trifluoromethyl)phenyl]methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215539-20-1 CAPLUS
CN Morpholine, 4-[[3-[(3,5-bis(trifluoromethyl)phenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215539-24-5 CAPLUS
CN Morpholine, 4-[[3-[(2,4-dichlorophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215539-25-6 CAPLUS
CN Morpholine, 4-[[3-[(1,1'-biphenyl)-4-ylmethylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215539-77-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-chlorophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 215539-78-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(2-(trifluoromethyl)phenyl)methylene]- (9CI) (CA INDEX NAME)



RN 215539-79-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(3-methylphenyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 215539-80-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(4-methylphenyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 215539-81-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-chlorophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(3-methoxyphenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 215539-86-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2-chlorophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215539-87-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-chlorophenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215539-88-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]-3-[(2-(trifluoromethyl)phenyl)methylene]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 215539-82-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-fluorophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 215539-83-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2-fluorophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215539-84-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-ethylphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215539-85-8 CAPLUS


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215539-89-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(3-methylphenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215539-90-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-methylphenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215539-91-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-chlorophenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215539-92-7 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[(3-fluorophenyl)methylene]-2,3-dihydro-2-oxo-N-
[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215539-93-8 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[(2-fluorophenyl)methylene]-2,3-dihydro-2-oxo-N-
[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215539-94-9 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[(4-ethylphenyl)methylene]-2,3-dihydro-2-oxo-N-
[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 215539-98-3 CAPLUS
CN Morpholine,
4-[[2,3-dihydro-2-oxo-3-[(2-(trifluoromethyl)phenyl)methylene]-
1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 215539-99-4 CAPLUS
CN Morpholine,
4-[[2,3-dihydro-3-[(3-methylphenyl)methylene]-2-oxo-1H-indol-5-
yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 215540-00-4 CAPLUS
CN Morpholine,
4-[[2,3-dihydro-3-[(4-methylphenyl)methylene]-2-oxo-1H-indol-5-
yl)sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215539-95-0 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-3-[(3-methoxyphenyl)methylene]-2-oxo-
N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215539-96-1 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[(2-chlorophenyl)methylene]-2,3-dihydro-2-oxo-N-
[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215539-97-2 CAPLUS
CN Morpholine,
4-[[3-[(4-chlorophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-
yl)sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215540-01-5 CAPLUS
CN Morpholine,
4-[[3-[(3-chlorophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-
yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 215540-02-6 CAPLUS
CN Morpholine,
4-[[3-[(2-fluorophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-
yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 215540-03-7 CAPLUS
CN Morpholine,
4-[[3-[(3-fluorophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-
yl)sulfonyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215540-04-8 CAPLUS
CN Morpholine,
4-[[3-[(4-ethylphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215540-05-9 CAPLUS
CN Morpholine,
4-[[2,3-dihydro-3-[(3-methoxyphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215540-06-0 CAPLUS
CN Morpholine,
4-[[3-[(2-chlorophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 215540-62-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,3-difluorophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 215540-63-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-fluoro-4-methoxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215540-64-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,5-dimethylphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215540-65-1 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-N-methyl-3-(2-naphthalenyl)methylene)-
2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215540-59-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-ethoxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215540-60-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,4-dimethylphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215540-61-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,5-difluorophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 215540-66-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(4-phenoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 215540-67-3 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[[3-{4-(1,1-dimethylethyl)phenoxy}phenyl]methyl
enyl]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215540-68-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(3-(trifluoromethyl)phenoxy)phenyl)methylene]- (9CI) (CA INDEX NAME)




RN 215540-69-5 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[(4-ethoxyphenyl)methylene]-2,3-dihydro-2-oxo-N-
[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215540-70-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,4-dimethylphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215540-71-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,5-difluorophenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215540-72-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,3-difluorophenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215540-76-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(4-phenoxyphenyl)methylene]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215540-77-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-[4-(1,1-dimethylethyl)phenoxy]phenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215540-78-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(3-[4-(trifluoromethyl)phenoxy]phenyl)methylene]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215540-73-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-fluoro-4-methoxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215540-74-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,5-dimethylphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215540-75-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(2-naphthalenylmethylene)-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215540-79-7 CAPLUS
CN Morpholine, 4-[(3-[(4-ethoxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 215540-80-0 CAPLUS
CN Morpholine, 4-[(3-[(2,4-dimethylphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 215540-81-1 CAPLUS
CN Morpholine, 4-[(3-[(2,5-difluorophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215540-82-2 CAPLUS
CN Morpholine, 4-[[3-[(2,3-difluorophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215540-83-3 CAPLUS
CN Morpholine, 4-[[3-[(3-fluoro-4-methoxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215540-84-4 CAPLUS
CN Morpholine, 4-[[3-[(2,5-dimethylphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 215540-88-8 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-[[3-[(trifluoromethyl)phenoxy]phenyl]methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 215541-64-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[[3-(4-methylphenoxy)phenyl]methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 215541-65-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(3,4-dichlorophenoxy)phenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215541-66-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(3-hydroxy-4-methoxyphenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215540-85-5 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-(2-naphthalenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215540-86-6 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-[(4-phenoxyphenyl)methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215540-87-7 CAPLUS
CN Morpholine, 4-[[3-[[3-[(4-(1,1-dimethylethyl)phenoxy)phenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 215541-67-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(5-hydroxy-2-nitrophenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 215541-68-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[2,3-dihydroxyphenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 215541-69-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(3,4-dichlorophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215541-70-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(3,4-dichlorophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


Kamal Saeed

10141236


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215541-71-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-methoxyphenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215541-72-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(4-(1-methylethyl)phenyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 215541-73-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(4-propoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215541-78-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,3-dihydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215541-79-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dihydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215541-80-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,4-dichlorophenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 215541-74-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(3-(4-methylphenoxy)phenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 215541-75-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-(3,4-dichlorophenoxy)phenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215541-76-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(3-hydroxy-4-methoxyphenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215541-77-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(5-hydroxy-2-nitrophenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215541-81-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-methoxyphenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215541-82-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-(1-methylethyl)phenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215541-83-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(4-propoxyphenyl)methylene]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215541-84-7 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[3-(4-methylphenoxy)phenyl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215541-85-8 CAPLUS
CN Morpholine, 4-[[3-[[3-(3,4-dichlorophenoxy)phenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215541-86-9 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[3-(3-hydroxy-4-methoxyphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215541-90-5 CAPLUS
CN Morpholine, 4-[[3-[[3-(3,4-dichlorophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215541-91-6 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[2-methoxyphenyl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215541-92-7 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[4-(1-methylethyl)phenyl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215541-87-0 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[5-hydroxy-2-nitrophenyl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215541-88-1 CAPLUS
CN Morpholine, 4-[[3-[[3-(2,3-dihydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215541-89-2 CAPLUS
CN Morpholine, 4-[[3-[[3-(3,5-dihydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215541-93-8 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[4-propoxyphenyl]methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215542-53-3 CAPLUS
CN 1H-indole-5-sulfonamide, 2,3-dihydro-3-[[4-methoxy-3-methylphenyl]methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215542-54-4 CAPLUS
CN 1H-indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[[3-(phenylmethoxy)phenyl]methylene]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 215542-55-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(4-(phenylmethoxy)phenyl)methylene]- (9CI) (CA INDEX NAME)



RN 215542-56-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2-chloro-4-hydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215542-57-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2-chloro-4-hydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215542-58-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(3,4,5-trihydroxyphenyl)methylene]- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 215542-62-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(5-(hydroxymethyl)-2-furanyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 215542-63-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-methoxy-3-methylphenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215542-64-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(3-(phenylmethoxy)phenyl)methylene]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215542-65-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(4-(phenylmethoxy)phenyl)methylene]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 215542-59-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(3-(4-methoxyphenoxy)phenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215542-60-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-[3-(dimethylamino)propoxy]phenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215542-61-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(3-furanylmethylene)-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215542-66-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2-chloro-4-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215542-67-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2-chloro-4-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215542-68-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]-3-[(3,4,5-trihydroxyphenyl)methylene]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215542-69-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[3-(4-methoxyphenoxy)phenyl]methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215542-70-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-(3-(dimethylamino)propoxy)phenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215542-71-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(3-furanylmethylene)-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215542-75-9 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-[[4-(phenylmethoxy)phenyl]methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215542-76-0 CAPLUS
CN Morpholine, 4-[[3-[[2,3-dihydro-1,4-benzodioxin-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215542-77-1 CAPLUS
CN Morpholine, 4-[[3-[[2-chloro-4-hydroxyphenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215542-72-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[5-(hydroxymethyl)-2-furanyl]methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215542-73-7 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[4-methoxy-3-methylphenyl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215542-74-8 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-[[3-(phenylmethoxy)phenyl]methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215542-78-2 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-[[3,4,5-trihydroxyphenyl]methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215542-79-3 CAPLUS
CN Morpholine, 4-[[3-[[3-(4-methoxyphenoxy)phenyl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215542-80-6 CAPLUS
CN Morpholine, 4-[[3-[[4-(3-(dimethylamino)propoxy)phenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215542-81-7 CAPLUS
CN Morpholine, 4-[[3-(3-furanylmethylene)-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215542-82-8 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[5-(hydroxymethyl)-2-furanyl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215543-35-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-(3-quinolinylmethylene)- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 215543-43-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-(2-quinolinylmethylene)- (9CI) (CA INDEX NAME)




RN 215543-44-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(1-methyl-1H-indol-3-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 215543-45-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(2-methyl-1H-indol-3-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 215543-47-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(6-methyl-2-pyridinyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 215543-37-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-(4-quinolinylmethylene)- (9CI) (CA INDEX NAME)



RN 215543-39-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-methoxy-1-pyrrolidinyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215543-41-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-(3-thienylmethylene)- (9CI) (CA INDEX NAME)




L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 215543-48-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-bromo-2-thienyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 215543-49-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-butoxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 215543-50-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-(3-quinolinylmethylene)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215543-51-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215543-52-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-methoxy-1-pyrrolidinyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215543-53-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-(3-thienylmethylene)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215543-54-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-(2-quinolinylmethylene)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215543-58-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-bromo-2-thienyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215543-59-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-butoxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215543-60-5 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-(3-thienylmethylene)-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215543-55-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(1-methyl-1H-indol-3-yl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215543-56-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-methyl-1H-indol-3-yl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 215543-57-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(6-methyl-2-pyridinyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215543-61-6 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-(4-quinolinylmethylene)-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215543-62-7 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(2-methoxy-1-pyrrolidinyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215543-63-8 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-(3-thienylmethylene)-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215543-64-9 CAPLUS
 CN Morpholine, 4-[[2,3-dihydro-3-[(1-methyl-1H-indol-3-yl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215543-65-0 CAPLUS
 CN Morpholine,
 4-[[2,3-dihydro-3-[(1-methyl-1H-indol-3-yl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 215543-66-1 CAPLUS
 CN Morpholine,
 4-[[2,3-dihydro-3-[(2-methyl-1H-indol-3-yl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215543-90-1 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-1H-inden-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 215543-91-2 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-1H-inden-2-yl)methylene]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 215543-67-2 CAPLUS
 CN Morpholine, 4-[[3-[(4-bromo-2-thienyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 215543-68-3 CAPLUS
 CN Morpholine, 4-[[3-[(4-bromo-2-thienyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 215543-69-4 CAPLUS
 CN Morpholine,
 4-[[3-[(4-butoxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:147306 CAPLUS
 DOCUMENT NUMBER: 128:204803
 TITLE: Indolinone combinatorial libraries and related products and methods for the treatment of disease
 INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Hirth, Klaus
 INVENTOR(S): Peter; Shawver, Laura Kay; et al.
 PATENT ASSIGNEE(S): Sugan, Inc., USA; Tang, Peng Cho; Sun, Li; McMahon, Gerald
 SOURCE: PCT Int. Appl., 293 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 9
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807695	A1	19980226	WO 1997-US14736	19970820
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CN 1155838	A	19970730	CN 1996-190616	19960605
EP 929520	A1	19990721	EP 1997-939480	19970820
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
US 6147106	A	20001114	US 1997-915366	19970820
JP 2001503736	T2	20010321	JP 1998-510973	19970820
EP 1247803	A2	20021009	EP 2002-77564	19970820
EP 1247803	A3	20021016		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
AU 9741556	A1	19980306	AU 1997-41556	19970821
US 2002022626	A1	20020221	US 2000-617529	20000713
PRIORITY APPLN. INFO.:				
			US 1996-702232	A 19960823
			US 1996-31585P	P 19961205
			US 1996-31586P	P 19961205
			US 1996-31588P	P 19961205
			US 1996-32546P	P 19961205
			US 1996-32547P	P 19961205
			US 1997-45565P	P 19970505
			US 1997-45566P	P 19970505
			US 1997-45714P	P 19970505
			US 1997-45715P	P 19970505
			US 1997-46843P	P 19970505
			US 1996-45715P	P 19961205
			US 1997-31565P	P 19970505
			EP 1997-939480	A3 19970820
			US 1997-915366	A3 19970820
			WO 1997-US14736	W 19970820

OTHER SOURCE(S): MARPAT 128:204803
 GI

Kamal Saeed



I

AB The invention relates to indolinone derivs, capable of modulating, regulating, and/or inhibiting protein kinase signal transduction. The compds. are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis, and restenosis, and metabolic diseases such as diabetes. Inhibitors specific to the FLK protein kinase can be obtained by adding chem. substituents to the 3-[(indole-3-yl)methylene]-2-indolinone system, in particular at the 1' position of the indole ring. Indolinone compds. that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano[b]pyrrole moiety. Indolinone compds. that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate protein kinases. This invention also features novel hydrosol. indolinone compds. that are tyrosine kinase inhibitors, and related products and methods. Approx. 1200 title compds.,

such as I, were prep'd. by combinatorial condensation of certain (un)substituted indolinones with aldehydes at the 3-position. I gave complete inhibition of MET kinase at chimeric MET receptors in vitro. **203988-65-2P**, 3-[(2-Ethoxybenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203988-66-3P**, 3-[(Thien-2-yl)methylidene]-5-[(methylamino)sulfonyl]-2-indolinone **203988-67-4P**, 3-[(1-Methylpyrrol-2-yl)methylidene]-5-[(methylamino)sulfonyl]-2-indolinone **203988-68-5P**, 3-(4-Fluorobenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203988-69-6P**, 3-[(Indol-3-yl)methylidene]-5-[(methylamino)sulfonyl]-2-indolinone **203988-70-9P**, 3-[(2-Methylthien-5-yl)methylidene]-5-[(methylamino)sulfonyl]-2-indolinone **203988-71-0P**, 3-(4-Bromobenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203988-72-1P**, 3-[(Pyrrol-2-yl)methylidene]-5-[(methylamino)sulfonyl]-2-indolinone **203988-73-2P**, 3-(2-Hydroxy-6-methoxybenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203988-74-3P**, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidene]-5-[(methylamino)sulfonyl]-2-indolinone **203988-75-4P**, 3-(2-Ethoxybenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203988-76-5P**, 3-[(Thien-2-yl)methylidene]-5-[[[4-

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued) (trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203989-55-3P**, 3-[(1-Hydroxynaphth-2-yl)methylidene]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203989-56-4P**, 3-[(2-Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidene]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203989-57-5P**, 3-[(2-Methyl-3-(ethoxycarbonyl)furan-5-yl)methylidene]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203989-58-6P**, 3-[(2,3-Bis(methoxycarbonyl)-5-methylpyrrol-4-yl)methylidene]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203989-60-0P**, 3-(4-Chloro-3-nitrobenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203989-61-3P**, 3-(2,4-Dihydroxy-3-methylbenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203989-62-2P**, 3-(Furan-2-yl)methylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203989-64-4P**, 3-[(2-Nitrofuran-5-yl)methylidene]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203989-65-5P**, 3-[[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidene]-5-(morpholinosulfonyl)-2-indolinone **203989-66-6P**, 3-(3-Bromo-2-hydroxy-5-methoxybenzylidene)-5-(morpholinosulfonyl)-2-indolinone **203989-67-7P**, 3-[(1-Hydroxynaphth-2-yl)methylidene]-5-(morpholinosulfonyl)-2-indolinone **203989-68-8P**, 3-[[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidene]-5-(morpholinosulfonyl)-2-indolinone **203989-69-9P**, 3-[[[2-Methyl-3-(ethoxycarbonyl)furan-5-yl)methylidene]-5-(morpholinosulfonyl)-2-indolinone **203989-70-2P**, 3-[[[2,3-Bis(methoxycarbonyl)-5-methylpyrrol-4-yl)methylidene]-5-(morpholinosulfonyl)-2-indolinone **203989-71-3P**, 3-(4-Chloro-3-nitrobenzylidene)-5-(morpholinosulfonyl)-2-indolinone **203989-72-4P**, 3-(2,4-Dihydroxy-3-methylbenzylidene)-5-(morpholinosulfonyl)-2-indolinone **203989-73-5P**, 3-(Furan-2-yl)methylidene)-5-(morpholinosulfonyl)-2-indolinone **203989-74-6P**, 3-[[[2-Nitrofuran-5-yl)methylidene]-5-(morpholinosulfonyl)-2-indolinone **203990-15-2P**, 3-(4-Ethoxy-3-methoxybenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203990-16-3P**, 3-(3,4-Dihydroxybenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203990-17-4P**, 3-(2,4-Dimethoxybenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203990-18-5P**, 3-[[[2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidene]-5-[(methylamino)sulfonyl]-2-indolinone **203990-19-6P**, 3-(2,4,6-Trimethoxybenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203990-20-9P**, 3-(4-Hydroxybenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203990-21-0P**, 3-(4-(Dimethylamino)benzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203990-22-1P**, 3-(2-Chloro-4-fluorobenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203990-23-2P**, 3-(3-Nitrobenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203990-24-3P**, 3-(4-Fluoro-2-(trifluoromethyl)benzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203990-25-4P**, 3-(4-Ethoxy-3-methoxybenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203990-26-5P**, 3-(3,4-Dihydroxybenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203990-27-6P**, 3-(2,4-Dimethoxybenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203990-28-7P**, 3-[[[2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidene]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued) (trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203988-77-6P**, 3-[(1-Methylpyrrol-2-yl)methylidene]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203988-78-7P**, 3-(4-Fluorobenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203988-79-8P**, 3-[[[Indol-3-yl)methylidene]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203988-80-1P**, 3-[[[2-Methylthien-5-yl)methylidene]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203988-81-2P**, 3-(4-Bromobenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203988-82-3P**, 3-[(Pyrrol-2-yl)methylidene]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203988-83-4P**, 3-(2-Hydroxy-6-methoxybenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203988-84-5P**, 3-[[[3,4-Dibromo-2-

methylpyrrol-5-yl)methylidene]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203988-85-6P**, 3-(2-Ethoxybenzylidene)-5-(morpholinosulfonyl)-2-indolinone **203988-86-7P**, 3-[(Thien-2-yl)methylidene]-5-(morpholinosulfonyl)-2-indolinone **203988-87-8P**, 3-[(1-Methylpyrrol-2-yl)methylidene]-5-(morpholinosulfonyl)-2-indolinone **203988-88-9P**, 3-(4-Fluorobenzylidene)-5-(morpholinosulfonyl)-2-indolinone **203988-89-0P**, 3-[[[Indol-3-yl)methylidene]-5-(morpholinosulfonyl)-2-indolinone **203988-90-3P**, 3-[[[2-Methylthien-5-yl)methylidene]-5-(morpholinosulfonyl)-2-indolinone **203988-91-4P**, 3-(4-Bromobenzylidene)-5-(morpholinosulfonyl)-2-indolinone **203988-92-5P**, 3-[(Pyrrol-2-yl)methylidene]-5-(morpholinosulfonyl)-2-indolinone **203988-93-6P**, 3-(2-Hydroxy-6-methoxybenzylidene)-5-(morpholinosulfonyl)-2-indolinone **203988-94-7P**, 3-[[[3,4-Dibromo-2-methylpyrrol-5-yl)methylidene]-5-(morpholinosulfonyl)-2-indolinone **203989-35-9P**, 3-[[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidene]-5-[(methylamino)sulfonyl]-2-indolinone **203989-36-0P**, 3-(3-Bromo-2-hydroxy-5-methoxybenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203989-38-2P**, 3-[[[1-Hydroxynaphth-2-yl)methylidene]-5-[(methylamino)sulfonyl]-2-indolinone **203989-40-6P**, 3-[[[2-(Ethoxycarbonyl)-3-[2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidene]-5-[(methylamino)sulfonyl]-2-indolinone **203989-42-8P**, 3-[[[2-Methyl-3-(ethoxycarbonyl)furan-5-yl)methylidene]-5-[(methylamino)sulfonyl]-2-indolinone **203989-43-9P**, 3-[[[2,3-Bis(methoxycarbonyl)-5-methylpyrrol-4-yl)methylidene]-5-[(methylamino)sulfonyl]-2-indolinone **203989-45-1P**, 3-(4-Chloro-3-nitrobenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203989-46-2P**, 3-(2,4-Dihydroxy-3-methylbenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203989-48-4P**, 3-(Furan-2-yl)methylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203989-49-5P**, 3-[[[2-Nitrofuran-5-yl)methylidene]-5-[(methylamino)sulfonyl]-2-indolinone **203989-52-0P**, 3-[[[2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidene]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203989-53-1P**, 3-(3-Bromo-2-hydroxy-5-methoxybenzylidene)-5-[[[4-(trifluoromethyl)benzylidene]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203990-29-8P**, 3-(2,4,6-Trimethoxybenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203990-30-1P**, 3-(4-Hydroxybenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203990-31-2P**, 3-(4-(Dimethylamino)benzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203990-32-3P**, 3-(2-Chloro-4-fluorobenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203990-33-4P**, 3-(3-Nitrobenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203990-34-5P**, 3-(4-Fluoro-2-(trifluoromethyl)benzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203990-35-6P**, 3-(4-Ethoxy-3-methoxybenzylidene)-5-(morpholinosulfonyl)-2-indolinone **203990-36-7P**, 3-(3,4-Dihydroxybenzylidene)-5-(morpholinosulfonyl)-2-indolinone **203990-37-8P**, 3-(2,4-Dimethoxybenzylidene)-5-(morpholinosulfonyl)-2-indolinone **203990-38-9P**, 3-[[[2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidene]-5-(morpholinosulfonyl)-2-indolinone **203990-39-0P**, 3-(2,4,6-Trimethoxybenzylidene)-5-(morpholinosulfonyl)-2-indolinone **203990-40-3P**, 3-(4-Hydroxybenzylidene)-5-(morpholinosulfonyl)-2-indolinone **203990-41-4P**, 3-[[[4-(Dimethylamino)benzylidene]-5-(morpholinosulfonyl)-2-indolinone **203990-42-5P**, 3-(2-Chloro-4-fluorobenzylidene)-5-(morpholinosulfonyl)-2-indolinone **203990-43-6P**, 3-(3-Nitrobenzylidene)-5-(morpholinosulfonyl)-2-indolinone **203990-44-7P**, 3-(4-Fluoro-2-(trifluoromethyl)benzylidene)-5-(morpholinosulfonyl)-2-indolinone **203990-45-8P**, 3-(2,4,6-Trifluorobenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203990-46-9P**, 3-(4-Hydroxy-2-methoxybenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203990-47-0P**, 3-(3,4-Dimethoxybenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203990-48-1P**, 3-(2-Hydroxybenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203990-49-2P**, 3-(Benzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203990-50-3P**, 3-[[[2-(Methylthio)thien-5-yl)methylidene]-5-[(methylamino)sulfonyl]-2-indolinone **203990-51-4P**, 3-(2,4-Dihydroxy-6-methylbenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203990-52-5P**, 3-(3-Ethoxy-4-hydroxybenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203990-53-6P**, 3-(2-Hydroxy-5-methoxybenzylidene)-5-[(methylamino)sulfonyl]-2-indolinone **203990-54-7P**, 3-[[[Imidazol-2-yl)methylidene]-5-[(methylamino)sulfonyl]-2-indolinone **203990-55-8P**, 3-(2,4,6-Trifluorobenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203990-56-9P**, 3-(4-Hydroxy-2-methoxybenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203991-00-8P**, 3-(3,4-Dimethoxybenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203991-01-9P**, 3-(2-Hydroxybenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203991-02-0P**, 3-(2-Hydroxybenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203991-03-1P**, 3-(2-Hydroxybenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203991-04-2P**, 3-(Benzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203991-05-3P**, 3-[[[2-(Methylthio)thien-5-yl)methylidene]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203991-06-4P**, 3-(2,4-Dihydroxy-6-methylbenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203991-07-5P**, 3-(2,4-Dihydroxy-6-methylbenzylidene)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203991-08-6P**, 3-(3-Ethoxy-4-hydroxybenzylidene)-5-[[[4-

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)

(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203991-13-3P

3-(2-Hydroxy-5-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203991-16-6P, 3-[[[imidazol-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203991-20-2P, 3-(2,4,6-Trifluorobenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203991-23-5P, 3-(4-Hydroxy-2-methoxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203991-27-9P, 3-(2,4-Dimethoxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203991-31-5P, 3-(2-Hydroxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203991-32-6P, 3-(Benzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203991-33-7P, 3-[[[2-(Methylthio)thien-5-yl)methylidenyl]-5-(morpholiniosulfonyl)-2-indolinone 203991-34-8P, 3-(2,4-Dihydroxy-6-methylbenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203991-35-9P, 3-(3-Ethoxy-4-hydroxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203991-37-1P, 3-(2-Hydroxy-5-methoxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203991-39-3P, 3-[[[imidazol-2-yl)methylidenyl]-5-(morpholiniosulfonyl)-2-indolinone 203991-86-0P, 3-[[[1-Methylbenzimidazol-2-yl)methylidenyl]-5-(methylamino)sulfonyl]-2-indolinone 203991-87-2P,

3-[[[4-Chloro-1-methylpyrazol-3-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203991-88-3P, 3-(2-Methylthien-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203991-89-3P, 3-[[4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203991-90-6P, 3-(3-Chloromethyl)-2-hydroxy-5-nitrobenzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203991-91-7P, 3-[[[2-Chlorothien-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203991-92-8P, 3-[[[2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203991-93-9P, 3-(3-Tert-Butyl-4-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203991-94-0P,

3-(3-Bromo-5-tert-butyl-4-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203991-95-1P, 3-(3,5-Di-tert-butyl-4-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203991-96-2P, 3-[[[1-Methylbenzimidazol-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203991-97-3P, 3-[[[4-Chloro-1-methylpyrazol-3-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203991-98-4P, 3-[[[2,3-Dimethylthien-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203991-99-5P, 3-[[[4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-00-1P, 3-(3-Chloromethyl)-2-hydroxy-5-nitrobenzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-01-2P, 3-[[[2-Chlorothien-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-02-3P, 3-[[[2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-03-4P, 3-(3-Tert-Butyl-4-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-04-5P, 3-(3-Bromo-5-tert-butyl-4-hydroxybenzylidenyl)-5-[[[4-

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)

3-[[[4-(Trifluoromethyl)benzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-74-1P, 3-(3-Tert-Butyl-4-hydroxy-5-nitrobenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203992-77-2P, 3-(2,4,6-Trihydroxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203992-78-3P, 3-[[[2-Nitrothien-5-yl)methylidenyl]-5-(morpholiniosulfonyl)-2-indolinone 203992-79-4P, 3-(4-Carboxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203992-80-7P, 3-(2,4-Difluorobenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203992-81-8P,

3-(3,5-Dimethyl-4-hydroxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203992-82-9P, 3-(3-Tert-Butyl-5-chloro-4-hydroxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203992-83-0P, 3-[[[2-Nitrothien-4-yl)methylidenyl]-5-(morpholiniosulfonyl)-2-indolinone 203992-84-1P, 3-[[[Di-n-butylamino)benzylidenyl]-5-(morpholiniosulfonyl)-2-indolinone 203992-85-2P, 3-[[[4-(Trifluoromethyl)benzylidenyl]-5-(morpholiniosulfonyl)-2-indolinone 203992-85-3P, 3-(2,4-Trihydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203992-86-4P,

3-(2-Hydroxy-3-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203993-27-5P, 3-(3-Bromo-4,5-dihydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203993-28-6P, 3-(3,4-Diacetoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203993-29-7P, 3-(4-Hydroxy-3-methylbenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203993-30-0P, 3-(2-Bromobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203993-31-1P, 3-(2,4-Dihydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203993-32-2P,

3-(2-Hydroxy-4-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203993-33-3P, 3-(3-Bromobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203993-34-4P, 3-(3,5-Di-tert-butyl-2-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203993-35-5P, 3-(2,3,4-Trihydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203993-36-6P,

3-(2-Hydroxy-3-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203993-37-7P, 3-(3-Bromo-4,5-dihydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203993-38-8P, 3-(3,4-Diacetoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203993-39-9P,

3-(4-Hydroxy-3-methylbenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203993-40-2P, 3-(2-Bromobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203993-41-3P, 3-(2,4-Dihydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203993-42-4P,

3-(2-Hydroxy-4-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203993-43-5P, 3-(3-Bromobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203993-44-6P, 3-(3,5-Di-tert-butyl-2-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203993-45-7P, 3-(2,3,4-Trihydroxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203993-46-8P, 3-(2-Hydroxy-3-methoxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203993-47-9P, 3-(3-Bromo-4,5-dihydroxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)

(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-05-6P, 3-(3,5-Di-tert-butyl-4-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-06-7P, 3-[[[1-Methylbenzimidazol-2-yl)methylidenyl]-5-(morpholiniosulfonyl)-2-indolinone 203992-07-8P, 3-[[[4-Chloro-1-methylpyrazol-3-yl)methylidenyl]-5-(morpholiniosulfonyl)-2-indolinone 203992-08-9P, 3-[[[2,3-Dimethylthien-5-yl)methylidenyl]-5-(morpholiniosulfonyl)-2-indolinone 203992-09-0P, 3-[[[4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-(morpholiniosulfonyl)-2-indolinone 203992-10-3P, 3-(3-Chloromethyl)-2-hydroxy-5-nitrobenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203992-11-4P, 3-[[[2-Chlorothien-5-yl)methylidenyl]-5-(morpholiniosulfonyl)-2-indolinone 203992-12-5P, 3-[[[2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-(morpholiniosulfonyl)-2-indolinone 203992-13-6P,

3-(3-Tert-Butyl-4-hydroxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203992-14-7P, 3-(3-Bromo-5-tert-butyl-4-hydroxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203992-15-8P, 3-(3,5-Di-tert-butyl-4-hydroxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203992-56-7P, 3-(3-Tert-Butyl-4-hydroxy-5-nitrobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203992-57-8P, 3-(2,4,6-Trihydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203992-58-9P,

3-[[[2-Nitrothien-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203992-59-0P, 3-(4-Carboxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203992-60-3P, 3-(2,4-Difluorobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203992-61-4P, 3-(3,5-Dimethyl-4-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203992-62-5P, 3-(3-Tert-Butyl-5-chloro-4-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203992-63-6P, 3-[[[2-Nitrothien-4-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203992-64-7P,

3-(4-Di-n-butylamino)benzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203992-65-8P, 3-[[[4-(Trifluoromethyl)benzylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203992-66-9P, 3-(3-Tert-Butyl-4-hydroxy-5-nitrobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-67-0P,

3-(2,4,6-Trihydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-68-1P, 3-(2-Nitrothien-5-yl)methylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-69-2P, 3-(4-Carboxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-70-5P,

3-(2,4-Difluorobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-71-6P, 3-(3,5-Dimethyl-4-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-72-7P, 3-(3-Tert-Butyl-5-chloro-4-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-73-8P, 3-[[[2-Nitrothien-4-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-74-9P, 3-(4-Di-n-butylamino)benzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203992-75-0P,

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)

203993-48-0P, 3-(3,4-Diacetoxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203993-49-1P, 3-(4-Hydroxy-3-methylbenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203993-50-4P, 3-(2-Bromobenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203993-51-5P, 3-(2,4-Dihydroxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203993-52-6P, 3-(2-Hydroxy-4-methoxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203993-53-7P, 3-(3-Bromobenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203993-54-8P, 3-(3,5-Di-tert-butyl-2-hydroxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203993-55-9P,

3-[[[1-(Dimethylamino)naphth-4-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203993-93-5P, 3-(4-Hydroxy-3-nitrobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203993-94-6P, 3-(3-Hydroxy-4-nitrobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203993-95-7P, 3-[[[8-Hydroxy-2,3,6,7-tetrahydro-1H,5H-benzo[i]quinolizin-9-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203993-96-8P, 3-(3,5-Diisopropyl-4-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 203993-97-9P, 3-[[[Benzo[b]furan-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203993-98-0P,

3-[[[1-(4-Chlorophenyl)pyrrol-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203993-99-1P, 3-[[[2-Ethylfuran-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203994-00-7P, 3-[[[3,4-Dimethylthieno[2,3-b]thien-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203994-01-8P, 3-[[[1-(Dimethylamino)naphth-4-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203994-02-9P,


3-(4-Hydroxy-3-nitrobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203994-03-0P, 3-(3-Hydroxy-4-nitrobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203994-04-1P, 3-[[[8-Hydroxy-2,3,6,7-tetrahydro-1H,5H-benzo[i]quinolizin-9-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203994-05-2P, 3-(3,5-Diisopropyl-4-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203994-06-3P, 3-[[[Benzo[b]furan-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203994-07-4P, 3-[[[1-(4-Chlorophenyl)pyrrol-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203994-08-5P,

3-[[[2-Ethylfuran-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203994-09-6P, 3-[[[3,4-Dimethylthieno[2,3-b]thien-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203994-10-7P, 3-[[[1-(Dimethylamino)naphth-4-yl)methylidenyl]-5-(morpholiniosulfonyl)-2-indolinone 203994-11-0P, 3-(4-Hydroxy-3-nitrobenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203994-12-1P, 3-(3-Hydroxy-4-nitrobenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203994-13-2P, 3-[[[8-Hydroxy-2,3,6,7-tetrahydro-1H,5H-benzo[i]quinolizin-9-yl)methylidenyl]-5-(morpholiniosulfonyl)-2-indolinone 203994-14-3P, 3-(3,5-Diisopropyl-4-hydroxybenzylidenyl)-5-(morpholiniosulfonyl)-2-indolinone 203994-15-4P, 3-[[[Benzo[b]furan-2-yl)methylidenyl]-5-(morpholiniosulfonyl)-2-indolinone


RL: BAC (Biological activity or effector, except adverse); BSU (Biological

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and testing of indolinone combinatorial library as protein
kinase inhibitors)
RN 203988-65-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2-ethoxyphenyl)methylene]-2,3-dihydro-N-
methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203988-66-3 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-N-methyl-2-oxo-3-(2-thienylmethylene)-
(9CI) (CA INDEX NAME)




RN 203988-67-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(1-methyl-1H-pyrrol-2-
yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 203988-68-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-fluorophenyl)methylene]-2,3-dihydro-N-
methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-(1H-pyrrol-2-
ylmethylene)- (9CI) (CA INDEX NAME)




RN 203988-73-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-hydroxy-6-
methoxyphenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203988-74-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-
yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203988-75-4 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[(2-ethoxyphenyl)methylene]-2,3-dihydro-2-oxo-N-
[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203988-69-6 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-3-(1H-indol-3-ylmethylene)-N-methyl-2-
oxo- (9CI) (CA INDEX NAME)



RN 203988-70-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(5-methyl-2-
thienyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 203988-71-0 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[(4-bromophenyl)methylene]-2,3-dihydro-N-methyl-
2-oxo- (9CI) (CA INDEX NAME)




RN 203988-72-1 CAPLUS


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 203988-76-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-(2-thienylmethylene)-N-[4-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203988-77-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(1-methyl-1H-pyrrol-2-
yl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203988-78-7 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[(4-fluorophenyl)methylene]-2,3-dihydro-2-oxo-N-
[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203988-79-8 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-N-[4-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Kamal Saeed

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203988-80-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(5-methyl-2-thienyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203988-81-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-(4-bromophenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203988-82-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(1H-pyrrol-2-yl)methylene]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203988-86-7 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-(2-thienylmethylene)-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203988-87-8 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(1-methyl-1H-pyrrol-2-yl)methylene]-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203988-88-9 CAPLUS
CN Morpholine, 4-[[3-[(4-fluorophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203988-83-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-hydroxy-6-methoxyphenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203988-84-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203988-85-6 CAPLUS
CN Morpholine, 4-[[3-[(2-ethoxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203988-89-0 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203988-90-3 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(5-methyl-2-thienyl)methylene]-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203988-91-4 CAPLUS
CN Morpholine, 4-[[3-[(4-bromophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203988-92-5 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-1-(1H-pyrrol-2-ylmethylene)-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203988-92-6 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(2-hydroxy-6-methoxyphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203988-94-7 CAPLUS
CN Morpholine, 4-[[3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203989-40-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-42-8 CAPLUS
CN 3-Furancarboxylic acid, 4-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-43-9 CAPLUS
CN 1H-Pyrrole-2,3-dicarboxylic acid, 4-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-, dimethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203989-35-9 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-36-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-bromo-2-hydroxy-5-methoxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203989-38-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(1-hydroxy-2-naphthalenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203989-45-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-chloro-3-nitrophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203989-46-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,4-dihydroxy-3-methylphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203989-48-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2-furanylmethylene)-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203989-49-5 CAPLUS


Kamal Saeed

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(5-nitro-2-furanyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 203989-52-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-2-oxo-5-[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-53-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-bromo-2-hydroxy-5-methoxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203989-55-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(1-hydroxy-2-naphthalenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203989-60-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-chloro-3-nitrophenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203989-61-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,4-dihydroxy-3-methylphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203989-62-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(2-furanylmethylene)-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203989-56-4 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-2-oxo-5-[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-57-5 CAPLUS
CN 3-Furancarboxylic acid, 5-[[1,2-dihydro-2-oxo-5-[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-58-6 CAPLUS
CN 1H-Pyrrole-2,3-dicarboxylic acid, 4-[[1,2-dihydro-2-oxo-5-[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-2-methyl-, dimethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203989-64-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(5-nitro-2-furanyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203989-65-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-66-6 CAPLUS
CN Morpholine, 4-[[3-[(3-bromo-2-hydroxy-5-methoxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203989-67-7 CAPLUS
CN Morpholine,
4-[[2,3-dihydro-3-[[1-hydroxy-2-naphthalenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203989-68-8 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-ethyl ester (9CI) (CA INDEX NAME)




RN 203989-69-9 CAPLUS
CN 3-Furancarboxylic acid,
5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203989-73-5 CAPLUS
CN Morpholine, 4-[[3-(2-furanylmethylene)-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203989-74-6 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[5-nitro-2-furanyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203990-15-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-ethoxy-3-methoxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203989-70-2 CAPLUS
CN 1H-Pyrrole-2,3-dicarboxylic acid, 4-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-, dimethyl ester (9CI) (CA INDEX NAME)




RN 203989-71-3 CAPLUS
CN Morpholine,
4-[[3-[[4-chloro-3-nitrophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203989-72-4 CAPLUS
CN Morpholine,
4-[[3-[[2,4-dihydroxy-3-methylphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203990-16-3 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[[3,4-dihydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203990-17-4 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[[2,4-dimethoxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203990-18-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203990-19-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[[2,4,6-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)


Kamal Saeed

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203990-20-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-hydroxyphenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203990-21-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-(dimethylamino)phenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203990-22-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2-chloro-4-fluorophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203990-23-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(3-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203990-27-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,4-dimethoxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203990-28-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203990-29-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]-3-[(2,4,6-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203990-24-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-fluoro-2-(trifluoromethyl)phenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203990-25-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-ethoxy-3-methoxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203990-26-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,4-dihydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203990-30-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-hydroxyphenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203990-31-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-(dimethylamino)phenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203990-32-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2-chloro-4-fluorophenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203990-33-4 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-3-[(3-nitrophenyl)methylene]-2-oxo-N-
[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203990-34-5 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[[4-fluoro-2-(trifluoromethyl)phenyl]methylene]-
2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203990-35-6 CAPLUS
CN Morpholine,
4-[[3-[(4-ethoxy-3-methoxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 203990-38-9 CAPLUS
CN Morpholine, 4-[[3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203990-39-0 CAPLUS
CN Morpholine,
4-[[2,3-dihydro-2-oxo-3-[(2,4,6-trimethoxyphenyl)methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203990-40-3 CAPLUS
CN Morpholine,
4-[[2,3-dihydro-3-[(4-hydroxyphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203990-41-4 CAPLUS
CN Morpholine, 4-[[3-[[4-(dimethylamino)phenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203990-36-7 CAPLUS
CN Morpholine, 4-[[3-[(3,4-dihydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203990-37-8 CAPLUS
CN Morpholine, 4-[[3-[(2,4-dimethoxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203990-42-5 CAPLUS
CN Morpholine, 4-[[3-[(2-chloro-4-fluorophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203990-43-6 CAPLUS
CN Morpholine,
4-[[2,3-dihydro-3-[(3-nitrophenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203990-44-7 CAPLUS
CN Morpholine, 4-[[3-[[4-fluoro-2-(trifluoromethyl)phenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203990-85-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(2,4,6-trifluorophenyl)methylene]- (9CI) (CA INDEX NAME)




RN 203990-86-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-hydroxy-2-methoxyphenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203990-87-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,4-dimethoxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203990-92-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-ethoxy-4-hydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203990-93-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-hydroxy-5-methoxyphenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203990-94-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(1H-imidazol-2-yl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203990-96-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-oxo-N-[4-(trifluoromethyl)phenyl]-3- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203990-88-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-hydroxyphenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203990-89-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 203990-90-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[[5-(methylthio)-2-thienyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 203990-91-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,4-dihydroxy-6-methylphenyl)methylene]-2,3- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
[(2,4,6-trifluorophenyl)methylene]- (9CI) (CA INDEX NAME)



RN 203990-98-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-hydroxy-2-methoxyphenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203991-00-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,4-dimethoxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203991-02-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-hydroxyphenyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203991-04-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-(phenylmethylene)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203991-05-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[5-(methylthio)-2-thienyl]methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203991-07-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,4-dihydroxy-6-methylphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203991-20-2 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-[(2,4,6-trifluorophenyl)methylene]-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203991-23-5 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(4-hydroxy-2-methoxyphenyl)methylene]-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203991-27-9 CAPLUS
CN Morpholine, 4-[[3-[(3,4-dimethoxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203991-10-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-ethoxy-4-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203991-13-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-hydroxy-5-methoxyphenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203991-16-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-imidazol-2-ylmethylene)-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203991-31-5 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(2-hydroxyphenyl)methylene]-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203991-32-6 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-(phenylmethylene)-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203991-33-7 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(5-(methylthio)-2-thienyl)methylene]-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203991-34-8 CAPLUS
CN Morpholine,
4-[[3-[(2,4-dihydroxy-6-methylphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203991-35-9 CAPLUS
CN Morpholine,
4-[[3-[(3-ethoxy-4-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203991-37-1 CAPLUS


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203991-88-2 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[(4,5-dimethyl-2-thienyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203991-89-3 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-N-methyl-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 203991-90-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(chloromethyl)-2-hydroxy-5-nitrophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203991-91-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(5-chloro-2-thienyl)methylene]-2,3-dihydro-N-


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Morpholine,
4-[[2,3-dihydro-3-[(2-hydroxy-5-methoxyphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203991-39-3 CAPLUS
CN Morpholine,
4-[[2,3-dihydro-3-(1H-imidazol-2-ylmethylene)-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203991-86-0 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-N-methyl-3-[(1-methyl-1H-benzimidazol-2-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 203991-87-1 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[(4-chloro-1-methyl-1H-pyrazol-3-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203991-92-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dimethyl-1H-pyrazol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203991-93-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203991-94-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-bromo-5-(1,1-dimethylethyl)-4-hydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203991-95-1 CAPLUS


Kamal Saeed

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 1H-Indole-5-sulfonamide, 3-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203991-96-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[1-methyl-1H-benzimidazol-2-yl]methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203991-97-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-chloro-1-methyl-1H-pyrazol-3-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203991-98-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4,5-dimethyl-2-thienyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203992-02-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3,5-dimethyl-1H-pyrazol-2-yl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203992-03-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203992-04-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-bromo-5-(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203991-99-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[[4,5,6,7-tetrahydro-1H-indol-2-yl]methylene]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203992-00-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(chloromethyl)-2-hydroxy-5-nitrophenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203992-01-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(chloromethyl)-2-hydroxy-5-nitrophenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203992-05-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203992-06-7 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[1-methyl-1H-benzimidazol-2-yl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203992-07-8 CAPLUS
CN Morpholine, 4-[[3-[[4-chloro-1-methyl-1H-pyrazol-3-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203992-08-9 CAPLUS
CN Morpholine, 4-[[3-[(4,5-dimethyl-2-thienyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203992-09-0 CAPLUS
CN Morpholine, 4-[[3-[(2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203992-10-3 CAPLUS
CN Morpholine, 4-[[3-[(3-(chloromethyl)-2-hydroxy-5-nitrophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203992-14-7 CAPLUS
CN Morpholine, 4-[[3-[(3-bromo-5-(1,1-dimethylethyl)-4-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203992-15-8 CAPLUS
CN Morpholine, 4-[[3-[(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203992-56-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(1,1-dimethylethyl)-4-hydroxy-5-nitrophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203992-11-4 CAPLUS
CN Morpholine, 4-[[3-[(5-chloro-2-thienyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203992-12-5 CAPLUS
CN Morpholine, 4-[[3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203992-13-6 CAPLUS
CN Morpholine, 4-[[3-[(3-(1,1-dimethylethyl)-4-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203992-57-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(2,4,6-trihydroxyphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 203992-58-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(5-nitro-2-thienyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 203992-59-0 CAPLUS
CN Benzoic acid, 4-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]- (9CI) (CA INDEX NAME)




RN 203992-60-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,4-difluorophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


Kamal Saeed

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203992-61-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-hydroxy-3,5-dimethylphenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203992-62-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-chloro-5-(1,1-dimethylethyl)-4-hydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203992-63-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(5-nitro-3-thienyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203992-68-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(5-nitro-2-thienyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203992-69-2 CAPLUS
CN Benzoic acid, 4-[[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]- (9CI) (CA INDEX NAME)




RN 203992-70-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,4-difluorophenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 203992-64-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-(dibutylamino)phenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203992-65-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[[4-(trifluoromethyl)phenyl)methylene]- (9CI) (CA INDEX NAME)




RN 203992-66-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(1,1-dimethylethyl)-4-hydroxy-5-nitrophenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203992-67-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]-3-[[2,4,6-trihydroxyphenyl)methylene]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203992-71-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-hydroxy-3,5-dimethylphenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203992-72-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-chloro-5-(1,1-dimethylethyl)-4-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203992-73-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(5-nitro-3-thienyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203992-74-9 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[[4-(4-nitrothiophenyl)methylene]-2,3-dihydro-
2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203992-75-0 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]-3-
[[4-(trifluoromethyl)phenyl)methylene]- (9CI) (CA INDEX NAME)




RN 203992-76-1 CAPLUS


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203992-79-4 CAPLUS
CN Benzoic acid, 4-[[[3-[[2,3-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-
ylidene]methyl]- (9CI) (CA INDEX NAME)




RN 203992-80-7 CAPLUS
CN Morpholine, 4-[[[3-[[2,3-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-
ylidene]methyl]- (9CI) (CA INDEX NAME)




RN 203992-81-8 CAPLUS
CN Morpholine,
4-[[[3-[[2,3-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-
ylidene]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Morpholine, 4-[[[3-[[2,3-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-
ylidene]methyl]- (9CI) (CA INDEX NAME)




RN 203992-77-2 CAPLUS
CN Morpholine,
4-[[[3-[[2,3-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-
ylidene]methyl]- (9CI) (CA INDEX NAME)




RN 203992-78-3 CAPLUS
CN Morpholine, 4-[[[3-[[2,3-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-
ylidene]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203992-82-9 CAPLUS
CN Morpholine, 4-[[[3-[[2,3-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-
ylidene]methyl]- (9CI) (CA INDEX NAME)




RN 203992-83-0 CAPLUS
CN Morpholine, 4-[[[3-[[2,3-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-
ylidene]methyl]- (9CI) (CA INDEX NAME)



RN 203992-84-1 CAPLUS
CN Morpholine,
4-[[[3-[[2,3-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-
ylidene]methyl]- (9CI) (CA INDEX NAME)


10141236

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203992-85-2 CAPLUS
CN Morpholine,

4-[[2,3-dihydro-2-oxo-3-[[4-(trifluoromethyl)phenyl)methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203993-25-3 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(2,3,4-trihydroxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 203993-26-4 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-hydroxy-3-methoxyphenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 203993-30-0 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[(2-bromophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203993-31-1 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[(2,4-dihydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203993-32-2 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-hydroxy-4-methoxyphenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203993-33-3 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[(3-bromophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203993-27-5 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[(3-bromo-4,5-dihydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203993-28-6 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[3,4-bis(acetyloxy)phenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203993-29-7 CAPLUS


CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-hydroxy-3-methylphenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 203993-34-4 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[3,5-bis(1,1-dimethylethyl)-2-hydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203993-35-5 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]-3-[(2,3,4-trihydroxyphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 203993-36-6 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-hydroxy-3-methoxyphenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203993-37-7 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[(3-bromo-4,5-dihydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Kamal Saeed

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203993-38-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3,4-bis(acetyloxy)phenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203993-39-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[4-hydroxy-3-methylphenyl]methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203993-40-2 CAPLUS


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203993-43-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[2,3-dihydro-3-[[2-hydroxy-4-methoxyphenyl]methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203993-44-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3,5-bis(1,1-dimethylethyl)-2-hydroxyphenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203993-45-7 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-[[2,3,4-trihydroxyphenyl]methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)

CN 1H-Indole-5-sulfonamide, 3-[[2-bromophenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203993-41-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[2,4-dihydroxyphenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203993-42-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[2-hydroxy-4-methoxyphenyl]methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203993-46-8 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[2-hydroxy-3-methoxyphenyl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203993-47-9 CAPLUS
CN Morpholine, 4-[[3-[[3-bromo-4,5-dihydroxyphenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203993-48-0 CAPLUS
CN Morpholine, 4-[[3-[[3-bis(acetyloxy)phenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


Kamal Saeed

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203993-49-1 CAPLUS
CN Morpholine,
4-[[2,3-dihydro-3-[(4-hydroxy-3-methylphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203993-50-4 CAPLUS
CN Morpholine,
4-[[3-[(2-bromophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203993-51-5 CAPLUS
CN Morpholine, 4-[[3-[(2,4-dihydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 203993-54-8 CAPLUS
CN Morpholine,
4-[[3-[(3,5-bis(1,1-dimethylethyl)-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203993-92-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-(dimethylamino)-1-naphthalenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203993-93-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-hydroxy-3-nitrophenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203993-94-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(3-hydroxy-4-nitrophenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203993-52-6 CAPLUS
CN Morpholine,
4-[[2,3-dihydro-3-[(2-hydroxy-4-methoxyphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203993-53-7 CAPLUS
CN Morpholine,
4-[[3-[(3-bromophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203993-95-7 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-N-methyl-2-oxo-3-[(2,3,6,7-tetrahydro-8-hydroxy-1H,5H-benzo[ij]quinolizin-9-yl)methylene]- (9CI) (CA INDEX NAME)




RN 203993-96-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-hydroxy-3,5-bis(1-methylethyl)phenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203993-97-9 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-(2-benzofuranyl)methylene)-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203993-98-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203993-99-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-ethyl-2-furanyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203994-00-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,4-dimethylthieno[2,3-b]thien-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203994-04-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(2,3,6,7-tetrahydro-8-hydroxy-1H,5H-benzo[ij]quinolizin-9-yl)methylene]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203994-05-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-hydroxy-3,5-bis(1-methylethyl)phenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203994-06-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(2-benzofuranylmethylene)-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203994-01-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-(dimethylamino)-1-naphthalenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203994-02-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-hydroxy-3-nitrophenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203994-03-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(3-hydroxy-4-nitrophenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203994-07-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203994-08-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-ethyl-2-furanyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203994-09-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,4-dimethylthieno[2,3-b]thien-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203994-10-9 CAPLUS
CN Morpholine, 4-[[3-[[4-(dimethylamino)-1-naphthalenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203994-11-0 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(4-hydroxy-3-nitrophenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203994-12-1 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(3-hydroxy-4-nitrophenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 203994-15-4 CAPLUS
CN Morpholine, 4-[[3-(2-benzofuranylmethylene)-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




203994-16-5P, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-(morpholinofuonyl)-2-indolinone 203994-17-6P,
3-[(2-Ethylfuran-5-yl)methylidenyl]-5-(morpholinofuonyl)-2-indolinone
203994-18-7P, 3-[(3,4-Dimethylthieno[2,3-b]thien-2-yl)methylidenyl]-5-(morpholinofuonyl)-2-indolinone 203994-77-6P
3-[(3-Bromothiophen-2-yl)methylidenyl]-5-(methyamino)sulfonyl)-2-indolinone 203994-79-0P, 3-(2-Bromo-6-hydroxy-5-methoxybenzylidenyl)-5-[(methyamino)sulfonyl]-2-indolinone
203994-81-4P, 3-[(2-Methylfuran-5-yl)methylidenyl]-5-[(methyamino)sulfonyl]-2-indolinone 203994-83-6P,
3-[(3-Methylpyrazol-5-yl)methylidenyl]-5-[(methyamino)sulfonyl]-2-indolinone 203994-85-6P, 3-(2-Hydroxy-5-methoxy-4-methylbenzylidenyl)-5-[(methyamino)sulfonyl]-2-indolinone
203994-87-0P, 3-[(4-Formylpiperazin-1-yl)benzylidenyl]-5-[(methyamino)sulfonyl]-2-indolinone 203994-89-2P,
3-[(4-(Morpholino)benzylidenyl)-5-[(methyamino)sulfonyl]-2-indolinone
203994-91-6P, 3-[(2-Chloro-4-(methoxycarbonyl)-3-(methoxycarbonyl)phenyl)pyrrol-5-yl)methylidenyl]-5-[(methyamino)sulfonyl]-2-indolinone 203994-95-0P,
3-[(4-Bromo-2-(4-chlorophenyl)pyrazol-3-yl)methylidenyl]-5-[(methyamino)sulfonyl]-2-indolinone 203994-95-0P,
3-[(1-imidazol-4-yl)methylidenyl]-5-[(methyamino)sulfonyl]-2-indolinone
203994-97-2P, 3-[(3-Bromothiophen-2-yl)methylidenyl]-5-[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203994-99-4P
3-(2-Bromo-5-methoxybenzylidenyl)-5-[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203995-01-1P,
3-[(2-Methylfuran-5-yl)methylidenyl]-5-[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203995-03-3P,
3-[(3-Methylpyrazol-5-yl)methylidenyl]-5-[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203995-05-5P
3-(2-Hydroxy-6-methoxybenzylidenyl)-5-[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203995-07-7P,
3-[(4-(4-Formylpiperazin-1-yl)benzylidenyl)-5-[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203995-09-9P
3-[(4-(Morpholino)benzylidenyl)-5-[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203995-11-9P,
3-[(4-Bromo-2-(4-chlorophenyl)pyrazol-3-yl)methylidenyl]-5-[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203995-13-5P,
3-[(4-Bromo-2-(4-chlorophenyl)pyrazol-3-yl)methylidenyl]-5-[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203995-15-7P,
3-[(1-imidazol-4-yl)methylidenyl]-5-[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone 203995-17-9P,
3-[(3-Bromothiophen-2-yl)methylidenyl]-5-(morpholinofuonyl)-2-indolinone 203995-19-1P, 3-(2-Bromo-6-hydroxy-5-methoxybenzylidenyl)-5-


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203994-13-2 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-[(2,3,6,7-tetrahydro-8-hydroxy-1H,5H-benzo[*ij*]quinolizin-9-yl)methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203994-14-3 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[4-hydroxy-3,5-bis(1-methylethyl)phenyl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)

2-indolinone 203995-21-5P,
3-[(2-Methylfuran-5-yl)methylidenyl]-5-(morpholinousulfonyl)-2-indolinone
203995-22-6P, 3-[(3-Methylpyrazol-5-yl)methylidenyl]-5-(
morpholinousulfonyl)-2-indolinone 203995-23-7P,
3-(2-Hydroxy-6-methoxy-4-methylbenzylidenyl)-5-(morpholinousulfonyl)-2-
indolinone **203995-24-8P**, 3-[4-(Formylpiperazin-1-
yl)benzylidenyl]methylamino)sulfonyl]-2-indolinone **203995-25-9P**
3-[4-(Morpholino)benzylidenyl]-5-(morpholinousulfonyl)-2-indolinone
203995-26-0P, 3-[2-Chloro-4-(methoxycarbonyl)-3-

{(methoxycarbonyl)methyl}pyrrol-5-yl)methylidenyl]-5-(morpholinousulfonyl)-
2-indolinone **203995-27-1P**, 3-[[4-Bromo-2-(4-chlorophenyl)pyrazol-
3-yl)methylidenyl]-5-(morpholinousulfonyl)-2-indolinone
203995-28-2P, 3-{[Imidazol-4-yl)methylidenyl]-5-(
morpholinousulfonyl)-2-indolinone **20395-29-3P**,
3-{[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-
yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone
203995-67-9P, 3-(3-tert-Butyl-4-hydroxy-5-methylbenzylidenyl)-5-(
{methylamino)sulfonyl}-2-indolinone **203995-68-0P**,

3-[[2-Bromofuran-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone
203995-69-1P, 3-[[{3-Dimethylpyrrol-4-yl)methylidenyl]-5-
{(methylamino)sulfonyl}-2-indolinone **203995-70-4P**,
3-[(5,8-Dihydroxy-1,2,3,4-tetrahydronaphth-6-yl)methylidenyl]-5-
{(methylamino)sulfonyl}-2-indolinone **203995-71-5P**
203995-72-6P **203995-73-7P**, 3-[[2-Ethylthien-5-
yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone
203995-74-8P, 3-(4-Methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-
2-indolinone **203995-75-9P**, 3-[[2-Ethoxy-4-(trifluoromethyl)
(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-[[[4-(
trifluoromethyl)phenylamino]sulfonyl]-2-indolinone **203995-76-0P**
, 3-(3-tert-Butyl-4-hydroxy-5-methylbenzylidenyl)-5-[[[4-(
trifluoromethyl)phenylamino]sulfonyl]-2-indolinone **203995-77-1P*****,
3-[[2-Bromofuran-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenylamino]
sulfonyl]-2-indolinone ****203995-78-2P**, 3-[(1,3-Dimethylpyrrol-4-
yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenylamino]sulfonyl]-2-
indolinone **203995-79-3P**, 3-[(5,8-Dihydroxy-1,2,3,4-

tetrahydronaphth-6-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenylamino]su
lfonyl]-2-indolinone **203995-80-6P** **203995-81-7P**
203995-82-0P, 3-[[2-Ethylthien-5-yl)methylidenyl]-5-[[[4-(
trifluoromethyl)phenylamino]sulfonyl]-2-indolinone **203995-83-9P**

3-(4-Methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenylamino]sulfonyl]-
2-indolinone **203995-84-0P**, 3-[[2-(Ethoxycarbonyl)-4-

(methoxycarbonyl)-3-methylpyrrol-5-yl)methylidenyl]-5-(morpholinousulfonyl)-
2-indolinone **203995-85-2P**, 3-(3-tert-Butyl-4-hydroxy-5-
methylbenzylidenyl)-5-(morpholinousulfonyl)-2-indolinone
20395-86-2P, 3-[[2-Bromofuran-5-yl)methylidenyl]-5-(
morpholinousulfonyl)-2-indolinone **203995-87-3P**,
3-[(1,3-Dimethylpyrrol-4-yl)methylidenyl]-5-(morpholinousulfonyl)-2-
indolinone **203995-88-4P**, 3-[(5,8-Dihydroxy-1,2,3,4-
tetrahydronaphth-6-yl)methylidenyl]-5-(morpholinousulfonyl)-2-indolinone
203995-89-5P **203995-90-6P** **203995-91-9P**,
3-[[2-Ethylthien-5-yl)methylidenyl]-5-(morpholinousulfonyl)-2-indolinone
203995-92-0P, 3-(4-Methoxybenzylidenyl)-5-(morpholinousulfonyl)-2-
indolinone **203996-33-2P**, 3-[4-(Diethylamino)benzylidenyl]-5-(
{methylamino)sulfonyl}-2-indolinone **203996-33-2P**.

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 (trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203999-33-1P**
 , 3-[[[6-(isopropyl-1,4-benzopyron-3-yl)methylidene]]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203999-36-4P**
 , 3-[[[6-Methyl-1,4-benzopyron-3-yl)methylidene]]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203999-38-6P**
 , 3-[[[6-Nitro-1,4-benzopyron-3-yl)methylidene]]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203999-40-0P**
203999-42-2P, 3-[[[5-Methoxyindol-3-yl)methylidene]]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203999-44-4P**
203999-46-6P, 3-[[[2-(2-Nitrophenyl)furan-5-yl)methylidene]]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **203999-47-7P**
 , 3-[[[9-Ethylcarbazol-3-yl)methylidene]]-5-(morpholinosulfonyl)-2-indolinone **203999-48-8P**, 3-[[[6,7-Dimethyl-1,4-benzopyron-3-yl)methylidene]]-5-(morpholinosulfonyl)-2-indolinone **203999-49-9P**

3-[[[4-(Propen-2-yl)cyclohexen-1-yl)methylidene]]-5-(morpholinosulfonyl)-2-indolinone **203999-50-2P**, 3-[[[6-(isopropyl-1,4-benzopyron-3-yl)methylidene]]-5-(morpholinosulfonyl)-2-indolinone **203999-51-3P**


3-[[[6-Methyl-1,4-benzopyron-3-yl)methylidene]]-5-(morpholinosulfonyl)-2-indolinone **203999-52-4P**, 3-[[[6-Nitro-1,4-benzopyron-3-yl)methylidene]]-5-(morpholinosulfonyl)-2-indolinone **203999-53-5P**
203999-54-6P, 3-[[[5-Methoxyindol-3-yl)methylidene]]-5-(morpholinosulfonyl)-2-indolinone **203999-55-7P**
203999-56-8P, 3-[[[2-(2-Nitrophenyl)furan-5-yl)methylidene]]-5-(morpholinosulfonyl)-2-indolinone **204000-38-4P**
 , 3-(3,5-Diisopropyl-4-methoxybenzylidene)]-5-[(methylamino)sulfonyl]-2-indolinone **204000-39-5P**, 3-(3,5-Diisopropyl-4-phenoxybenzylidene)]-5-[(methylamino)sulfonyl]-2-indolinone **204000-40-8P**, 3-(3-tert-Butyl-4-methoxybenzylidene)]-5-[(methylamino)sulfonyl]-2-indolinone **204000-41-9P**, 3-[4-(Benzylloxy)-3-tert-butylbenzylidene]]-5-[(methylamino)sulfonyl]-2-indolinone **204000-42-0P**, 3-(3-Bromo-5-tert-butyl-4-methoxybenzylidene)]-5-[(methylamino)sulfonyl]-2-indolinone **204000-43-1P**, 3-[4-(Benzylloxy)-3-bromo-5-tert-butylbenzylidene]]-5-[(methylamino)sulfonyl]-2-indolinone **204000-44-2P**,

3-(3-tert-Butyl-5-chloro-4-methoxybenzylidene)]-5-[(methylamino)sulfonyl]-2-indolinone **204000-45-3P**, 3-[4-(Benzylloxy)-5-tert-butyl-3-chlorobenzyldiene]]-5-[(methylamino)sulfonyl]-2-indolinone **204000-46-4P**, 3-(3-tert-Butyl-5-iodo-4-methoxybenzylidene)]-5-[(methylamino)sulfonyl]-2-indolinone **204000-48-6P**
 , 3-(3,5-Diisopropyl-4-methoxybenzylidene)]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **204000-49-7P**
 , 3-(3,5-Diisopropyl-4-phenoxybenzylidene)]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **204000-50-0P**
 , 3-(3-tert-Butyl-4-methoxybenzylidene)]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **204000-51-1P**
 , 3-[4-(Benzylloxy)-3-tert-butylbenzylidene]]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **204000-52-2P**
 , 3-(3-Bromo-5-tert-butyl-4-methoxybenzylidene)]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **204000-53-3P**
 , 3-[4-(Benzylloxy)-3-bromo-5-tert-butylbenzylidene]]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **204000-54-4P**
 , 3-(3-tert-Butyl-5-chloro-4-methoxybenzylidene)]-5-[[[4-

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 (trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **204000-55-5P**
 , 3-[4-(Benzylloxy)-5-tert-butyl-3-chlorobenzyldiene]]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **204000-56-6P**
 , 3-(3-tert-Butyl-5-iodo-4-methoxybenzylidene)]-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-2-indolinone **204000-58-8P**
 , 3-(3,5-Diisopropyl-4-methoxybenzylidene)]-5-(morpholinosulfonyl)-2-indolinone **204000-59-9P**, 3-(3,5-Diisopropyl-4-phenoxybenzylidene)]-5-(morpholinosulfonyl)-2-indolinone **204000-60-2P**, 3-(3-tert-Butyl-4-methoxybenzylidene)]-5-(morpholinosulfonyl)-2-indolinone **204000-61-3P**, 3-[4-(Benzylloxy)-3-tert-butylbenzylidene]]-5-(morpholinosulfonyl)-2-indolinone **204000-62-4P**, 3-(3-Bromo-5-tert-butyl-4-methoxybenzylidene)]-5-(morpholinosulfonyl)-2-indolinone **204000-63-5P**, 3-[4-(Benzylloxy)-3-bromo-5-tert-butylbenzylidene]]-5-(morpholinosulfonyl)-2-indolinone


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and testing of indolinone combinatorial library as protein kinase inhibitors)

RN 203994-16-5 CAPLUS
 CN Morpholine, 4-[[3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203994-17-6 CAPLUS
 CN Morpholine, 4-[[3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203994-18-7 CAPLUS
 CN Morpholine, 4-[[3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 203994-77-8 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[3-bromo-2-thienyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203994-79-0 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[6-bromo-2-hydroxy-3-methoxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203994-81-4 CAPLUS


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[[5-methyl-2-furanyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 203994-83-6 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[[5-methyl-1H-pyrazol-3-yl)methylene]-2-oxo- (9CI) (CA INDEX NAME)



RN 203994-85-8 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[2-hydroxy-6-methoxy-4-methylphenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203994-87-0 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[4-(4-formyl-1-piperazinyl)phenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203994-89-2 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[[4-(4-morpholinyl)phenyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203994-91-6 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203994-93-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-bromo-1-(4-chlorophenyl)-1H-pyrazol-5-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203994-95-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(5-methyl-1H-pyrazol-3-yl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203995-03-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(5-methyl-1H-pyrazol-3-yl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203995-05-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-hydroxy-6-methoxy-4-methylphenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203995-07-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-formyl-1-piperazinyl)phenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203994-97-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(3-bromo-2-thienyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203994-99-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(6-bromo-2-hydroxy-3-methoxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203995-01-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(5-methyl-2-furanyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203995-09-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-(4-morpholinyl)phenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203995-11-3 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203995-13-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-bromo-1-(4-chlorophenyl)-1H-pyrazol-5-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203995-15-7 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-3-((1H-imidazol-4-yl)methylene)-2-oxo-N-
[(4-(trifluoromethyl)phenyl)]- (9CI) (CA INDEX NAME)




RN 203995-17-9 CAPLUS
CN Morpholine, 4-[[3-[(3-bromo-2-thienyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203995-19-1 CAPLUS
CN Morpholine, 4-[[3-[(6-bromo-2-hydroxy-3-methoxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203995-24-8 CAPLUS
CN Morpholine, 4-[[3-[(4-(4-formyl-1-piperazinyl)phenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203995-25-9 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(4-(4-morpholinyl)phenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203995-26-0 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[[1,2-dihydro-5-(4-morpholinyl)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203995-21-5 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(5-methyl-2-furanyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203995-22-6 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(5-methyl-1H-pyrazol-3-yl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203995-23-7 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(2-hydroxy-6-methoxy-4-methylphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203995-27-1 CAPLUS
CN Morpholine, 4-[[3-[(4-bromo-1-(4-chlorophenyl)-1H-pyrazol-5-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203995-28-2 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(1H-imidazol-4-yl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203995-66-8 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[1,2-dihydro-5-[(methilamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203995-67-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(1,1-dimethylethyl)-4-hydroxy-5-methylphenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203995-68-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-bromo-2-furanyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203995-69-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[1,4-dimethyl-1H-pyrrol-3-yl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203995-74-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-methoxyphenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203995-75-9 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-76-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(1,1-dimethylethyl)-4-hydroxy-5-methylphenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 203995-70-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[[5,6,7,8-tetrahydro-1,4-dihydroxy-2-naphthalenyl]methylene]- (9CI) (CA INDEX NAME)



RN 203995-71-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-fluoro-2,3-dihydro-2-oxo-1H-indol-3-yl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203995-72-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[2,3-dihydro-2-oxo-1H-indol-3-yl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203995-73-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-ethyl-2-thienyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203995-77-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[5-bromo-2-furanyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203995-78-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[1,4-dimethyl-1H-pyrrol-3-yl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203995-79-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[[5,6,7,8-tetrahydro-1,4-dihydroxy-2-naphthalenyl]methylene]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203995-80-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(5-fluoro-2,3-dihydro-2-oxo-1H-indol-3-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203995-81-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,3-dihydro-2-oxo-1H-indol-3-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203995-82-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(5-ethyl-2-thienyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203995-83-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-methoxyphenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203995-84-0 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-85-1 CAPLUS
CN Morpholine, 4-[[3-[(1,1-dimethylethyl)-4-hydroxy-5-methylphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203995-86-2 CAPLUS
CN Morpholine, 4-[[3-[(5-bromo-2-furanyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203995-87-3 CAPLUS
CN Morpholine, 4-[[3-[(1,4-dimethyl-1H-pyrrol-3-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203995-88-4 CAPLUS
CN Morpholine, 4-[[3-[(2,3-dihydro-2-oxo-3-[(5,6,7,8-tetrahydro-1,4-dihydroxy-2-naphthalenyl)methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203995-89-5 CAPLUS
CN Morpholine, 4-[[3-[(5-fluoro-2,3-dihydro-2-oxo-1H-indol-3-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203995-90-8 CAPLUS
CN Morpholine, 4-[[3-[(2,3-dihydro-2-oxo-1H-indol-3-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203995-91-9 CAPLUS
CN Morpholine, 4-[[3-[(5-ethyl-2-thienyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203995-92-0 CAPLUS


Kamal Saeed

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN Morpholine,
 4-[[2,3-dihydro-3-[(4-methoxyphenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203996-32-1 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 3-[[4-(diethylamino)phenyl]methylene]-2,3-dihydro-
 N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203996-33-2 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203996-34-3 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(3-bromo-5-chloro-2-hydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203996-38-7 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 3-[(3-cyanophenyl)methylene]-2,3-dihydro-N-methyl-
 2-oxo- (9CI) (CA INDEX NAME)



RN 203996-39-8 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 3-[(4-cyanophenyl)methylene]-2,3-dihydro-N-methyl-
 2-oxo- (9CI) (CA INDEX NAME)




RN 203996-40-1 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 3-[(2,5-dihydroxyphenyl)methylene]-2,3-dihydro-N-
 methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203996-41-2 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 3-[(2,3-dimethoxyphenyl)methylene]-2,3-dihydro-N-


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203996-35-4 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 3-[[2-[(4-chlorophenyl)thio]phenyl]methylene]-2,3-
 dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203996-36-5 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 3-[(6-chloro-1,3-benzodioxol-5-yl)methylene]-2,3-
 dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203996-37-6 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(4-oxo-4H-1-benzopyran-3-yl)methylene]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203996-42-3 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 3-[[4-(diethylamino)phenyl]methylene]-2,3-dihydro-
 2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203996-43-4 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203996-44-5 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(3-bromo-5-chloro-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203996-45-6 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[[2-[(4-chlorophenyl)thio]phenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203996-46-7 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[[6-chloro-1,3-benzodioxol-5-yl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203996-47-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[[4-oxo-4H-1-benzopyran-3-yl]methylene]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203996-51-4 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[[2,3-dimethoxyphenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203996-52-5 CAPLUS
CN Morpholine,
4-[[3-[[4-(diethylamino)phenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203996-53-6 CAPLUS
CN Morpholine, 4-[[3-[[3,5-diethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203996-48-9 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[[3-(3-cyanophenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203996-49-0 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[[4-(cyanophenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203996-50-3 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[[2,5-dihydroxyphenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203996-54-7 CAPLUS
CN Morpholine, 4-[[3-[[3-bromo-5-chloro-2-hydroxyphenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203996-55-8 CAPLUS
CN Morpholine,
4-[[3-[[2-[(4-chlorophenyl)thio]phenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203996-56-9 CAPLUS
CN Morpholine,
4-[[3-[[6-chloro-1,3-benzodioxol-5-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




Kamal Saeed


10141236

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 203996-57-0 CAPLUS
CN Morpholine, 4-[(2,3-dihydro-2-oxo-3-[(4-oxo-4H-1-benzopyran-3-yl)methylene]-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 203996-58-1 CAPLUS
CN Morpholine, 4-[(3-[(4-cyanophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203996-59-2 CAPLUS
CN Morpholine, 4-[(3-[(4-cyanophenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203997-04-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dimethoxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203997-05-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-(dimethylamino)-2-methoxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203997-06-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(9H-fluoren-2-ylmethylene)-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203997-07-3 CAPLUS

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 203996-60-5 CAPLUS
CN Morpholine, 4-[(3-[(2,5-dihydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 203996-61-6 CAPLUS
CN Morpholine, 4-[(3-[(2,3-dimethoxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203997-02-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,5-dimethoxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203997-03-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2,6-dimethoxyphenyl)methylene]-2,3-dihydro-N-

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


1H-Indole-5-sulfonamide, 3-[(2-fluoro-3-(trifluoromethyl)phenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203997-08-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2-fluoro-5-(trifluoromethyl)phenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203997-09-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(2-fluoro-6-(trifluoromethyl)phenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203997-10-8 CAPLUS
CN Acetic acid, [2-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)




10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 203997-11-9 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(7-methoxy-1,3-benzodioxol-5-yl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203997-12-0 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(2,5-dimethoxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203997-13-1 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(2,6-dimethoxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203997-14-2 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(3,5-dimethoxyphenyl)methylene]-2,3-dihydro-2-


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203997-15-3 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(4-(dimethylamino)-2-methoxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203997-16-4 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-(9H-fluoren-2-ylmethylene)-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203997-17-5 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(2-fluoro-3-(trifluoromethyl)phenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203997-18-6 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(2-fluoro-5-(trifluoromethyl)phenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203997-19-7 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(2-fluoro-6-(trifluoromethyl)phenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203997-20-0 CAPLUS
 CN Acetic acid, [2-[[[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203997-21-1 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(7-methoxy-1,3-benzodioxol-5-yl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203997-22-2 CAPLUS
 CN Morpholine, 4-[[[3-[(2,5-dimethoxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203997-23-3 CAPLUS
 CN Morpholine, 4-[[[3-[(2,6-dimethoxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203997-24-4 CAPLUS
CN Morpholine, 4-[[3-[(3,5-dimethoxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203997-25-5 CAPLUS
CN Morpholine, 4-[[3-[[4-(dimethylamino)-2-methoxyphenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203997-26-6 CAPLUS
CN Morpholine, 4-[[3-[(9H-fluoren-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203997-30-2 CAPLUS
CN Acetic acid, [2-[[1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 203997-31-3 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(7-methoxy-1,3-benzodioxol-5-yl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203997-72-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(2-methoxy-1-naphthalenyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203997-27-7 CAPLUS
CN Morpholine, 4-[[3-[(2-fluoro-3-(trifluoromethyl)phenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203997-28-8 CAPLUS
CN Morpholine, 4-[[3-[(2-fluoro-5-(trifluoromethyl)phenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203997-29-9 CAPLUS
CN Morpholine, 4-[[3-[(2-fluoro-6-(trifluoromethyl)phenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203997-73-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(4-methoxy-1-naphthalenyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 203997-74-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(4-methylthio)phenyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 203997-75-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[(3-methyl-2-thienyl)methylene]-2-oxo- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203997-76-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(3-phenoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 203997-77-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-(2-pyridinylmethylene)- (9CI) (CA INDEX NAME)




RN 203997-78-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-(3-pyridinylmethylene)- (9CI) (CA INDEX NAME)




RN 203997-79-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-(4-pyridinylmethylene)- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203997-81-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(4-(1-pyrrolidinyl)phenyl)methylene]- (9CI) (CA INDEX NAME)




RN 203997-83-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-(2-cyclohexen-1-ylmethylene)-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203997-85-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-methoxy-1-naphthalenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203997-87-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-methoxy-1-naphthalenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203997-89-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-methylthio)phenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203997-90-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(3-methyl-2-thienyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203997-91-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-(2-pyridinylmethylene)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203997-92-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-(3-pyridinylmethylene)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203997-93-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-(4-pyridinylmethylene)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203997-94-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-(4-pyridinylmethylene)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203997-95-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(4-(1-pyrrolidinyl)phenyl)methylene]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203997-96-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-(2-cyclohexen-1-ylmethylene)-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203997-97-1 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(2-methoxy-1-naphthalenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203997-98-2 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(4-methoxy-1-naphthalenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203997-99-3 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(4-(methylthio)phenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203998-00-9 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[(3-methyl-2-thienyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203998-01-0 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-[(3-phenoxyphenyl)methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203998-02-1 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-(2-pyridinylmethylene)-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203998-03-2 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-(3-pyridinylmethylene)-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203998-04-3 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-(4-pyridinylmethylene)-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203998-05-4 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-[(4-(1-pyrrolidinyl)phenyl)methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


Kamal Saeed

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203998-06-5 CAPLUS
CN Morpholine,
4-[[3-(2-cyclohexen-1-ylmethylene)-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203998-47-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(2,3,4-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 203998-48-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(2,4,5-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203998-53-2 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[(2-chloro-3-quinolinyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203998-54-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(6,8-dibromo-4-oxo-4H-1-benzopyran-3-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203998-55-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(4,5-dimethoxy-2-furanyl)methylene]- (9CI) (CA INDEX NAME)




RN 203998-56-5 CAPLUS
CN 1H-Indole-5-sulfonamide,
3-[(4,5-dimethyl-2-furanyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 203998-49-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(3,4,5-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 203998-50-9 CAPLUS
CN 1H-Indole, 1-acetyl-3-[(1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 203998-51-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(6-chloro-4-oxo-4H-1-benzopyran-3-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203998-52-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(5-(2-chlorophenyl)-2-furanyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203998-57-6 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-2-oxo-N-(4-(trifluoromethyl)phenyl)-3-[(2,3,4-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 203998-58-7 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-2-oxo-N-(4-(trifluoromethyl)phenyl)-3-[(2,4,5-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 203998-59-8 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-2-oxo-N-(4-(trifluoromethyl)phenyl)-3-[(3,4,5-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203998-60-1 CAPLUS
CN 1H-Indole, 1-acetyl-3-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 203998-61-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[[6-chloro-4-oxo-4H-1-benzopyran-3-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203998-62-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[[5-(2-chlorophenyl)-2-furanyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203998-66-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[[4,5-dimethyl-2-furanyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203998-67-8 CAPLUS
CN Morpholine, 4-[[[2,3-dihydro-2-oxo-3-[(2,3,4-trimethoxyphenyl)methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203998-68-9 CAPLUS
CN Morpholine, 4-[[[2,3-dihydro-2-oxo-3-[(2,3,4-trimethoxyphenyl)methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203998-63-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[[2-chloro-3-quinoliny)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203998-64-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[[6,8-dibromo-4-oxo-4H-1-benzopyran-3-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203998-65-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(tetrahydro-2,5-dimethoxy-3-furanyl)methylene]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203998-69-0 CAPLUS
CN Morpholine, 4-[[[2,3-dihydro-2-oxo-3-[(3,4,5-trimethoxyphenyl)methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203998-70-3 CAPLUS
CN 1H-Indole, 1-acetyl-3-[[[1,2-dihydro-5-(4-morpholinyl)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 203998-71-4 CAPLUS
CN Morpholine, 4-[[[3-[[[6-chloro-4-oxo-4H-1-benzopyran-3-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203998-72-5 CAPLUS
CN Morpholine, 4-[[3-[[5-(2-chlorophenyl)-2-furanyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203998-73-6 CAPLUS
CN Morpholine, 4-[[3-[[2-chloro-3-quinolinyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203998-74-7 CAPLUS
CN Morpholine, 4-[[3-[[6,8-dibromo-4-oxo-4H-1-benzopyran-3-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 203999-21-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[[6,7-dimethyl-4-oxo-4H-1-benzopyran-3-yl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203999-22-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[[4-(1-methylethenyl)-1-cyclohexen-1-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 203999-23-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[[6-(1-methylethyl)-4-oxo-4H-1-benzopyran-3-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 203999-24-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[[6-methyl-4-oxo-4H-1-benzopyran-3-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203998-75-8 CAPLUS
CN Morpholine, 4-[[3-[[2,3-dihydro-2-oxo-3-[[tetrahydro-2,5-dimethoxy-3-furanyl]methylene]-1H-indol-5-yl]sulfonyl]-morpholine. (9CI) (CA INDEX NAME)



RN 203998-76-9 CAPLUS
CN Morpholine, 4-[[3-[[4,5-dimethyl-2-furanyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203999-20-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[9-ethyl-9H-carbazol-3-yl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 203999-25-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[[6-nitro-4-oxo-4H-1-benzopyran-3-yl]methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 203999-26-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[[1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]methylene]- (9CI) (CA INDEX NAME)



RN 203999-27-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[5-methoxy-1H-indol-3-yl]methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 203999-28-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[2,3-dihydro-1-methyl-2-oxo-1H-indol-3-yl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




10141236

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 203999-29-5 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-[[5-(2-nitrophenyl)-2-furanyl]methylene]-2-oxo- (9CI) (CA INDEX NAME)




RN 203999-30-8 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[(9-ethyl-9H-carbazol-3-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203999-31-9 CAPLUS


CN 1H-Indole-5-sulfonamide, 3-[(6,7-dimethyl-4-oxo-4H-1-benzopyran-3-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203999-32-0 CAPLUS


CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[4-(1-methylethenyl)-1-cyclohexen-1-yl]methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203999-40-0 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)methylene]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203999-42-2 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203999-44-4 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[(2,3-dihydro-1-methyl-2-oxo-1H-indol-3-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 203999-33-1 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[6-(1-methylethyl)-4-oxo-4H-1-benzopyran-3-yl]methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203999-36-4 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(6-methyl-4-oxo-4H-1-benzopyran-3-yl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203999-38-6 CAPLUS


CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(6-nitro-4-oxo-4H-1-benzopyran-3-yl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 203999-46-6 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[5-(2-nitrophenyl)-2-furanyl]methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203999-47-7 CAPLUS

CN Morpholine, 4-[[3-[(9-ethyl-9H-carbazol-3-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203999-48-8 CAPLUS

CN Morpholine, 4-[[3-[(6,7-dimethyl-4-oxo-4H-1-benzopyran-3-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203999-49-9 CAPLUS


CN Morpholine, 4-[[2,3-dihydro-3-[[4-(1-methylethenyl)-1-cyclohexen-1-yl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




Kamal Saeed

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203999-50-2 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[6-(1-methylethyl)-4-oxo-4H-1-benzopyran-3-yl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203999-51-3 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[6-methyl-4-oxo-4H-1-benzopyran-3-yl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203999-52-4 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[6-nitro-4-oxo-4H-1-benzopyran-3-yl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203999-56-8 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[5-(2-nitrophenyl)-2-furanyl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204000-38-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[4-methoxy-3,5-bis(1-methylethyl)phenyl]methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204000-39-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[3,5-bis(1-methylethyl)-4-phenoxyphenyl]methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 203999-53-5 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-[[1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]methylene]-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203999-54-6 CAPLUS
CN Morpholine, 4-[[2,3-dihydro-3-[[5-methoxy-1H-indol-3-yl]methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203999-55-7 CAPLUS
CN Morpholine, 4-[[3-[[2,3-dihydro-1-methyl-2-oxo-1H-indol-3-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 204000-40-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(1,1-dimethylethyl)-4-methoxyphenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 204000-41-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(1,1-dimethylethyl)-4-(phenylmethoxy)phenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204000-42-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-bromo-5-(1,1-dimethylethyl)-4-methoxyphenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




Kamal Saeed

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 204000-43-1 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[3-bromo-5-(1,1-dimethylethyl)-4-(phenylmethoxy)phenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 204000-44-2 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[3-chloro-5-(1,1-dimethylethyl)-4-methoxyphenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204000-45-3 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[3-chloro-5-(1,1-dimethylethyl)-4-(phenylmethoxy)phenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204000-46-4 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[3-(1,1-dimethylethyl)-5-iodo-4-methoxyphenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204000-48-6 CAPLUS
 CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[4-methoxy-3-bis(1-methylethyl)phenyl]methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204000-49-7 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[3,5-bis(1-methylethyl)-4-phenoxyphenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204000-50-0 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[3-(1,1-dimethylethyl)-4-methoxyphenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204000-51-1 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[3-(1,1-dimethylethyl)-4-(phenylmethoxy)phenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204000-52-2 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[3-bromo-5-(1,1-dimethylethyl)-4-methoxyphenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204000-53-3 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[3-bromo-5-(1,1-dimethylethyl)-4-(phenylmethoxy)phenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204000-54-4 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[3-chloro-5-(1,1-dimethylethyl)-4-methoxyphenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 204000-55-5 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[3-chloro-5-(1,1-dimethylethyl)-4-(phenylmethoxy)phenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204000-56-6 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[[3-(1,1-dimethylethyl)-5-iodo-4-methoxyphenyl]methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Kamal Saeed

10141236

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
methoxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 204000-58-8 CAPLUS
CN Morpholine, 4-[[[2,3-dihydro-3-[[4-methoxy-3,5-bis(1-methylethyl)phenyl)methylene]-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204000-59-9 CAPLUS
CN Morpholine, 4-[[[3-[[[3,5-bis(1-methylethyl)-4-phenoxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204000-60-2 CAPLUS
CN Morpholine, 4-[[[3-[[[3-(1,1-dimethylethyl)-4-methoxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204000-61-3 CAPLUS
CN Morpholine, 4-[[[3-[[[3-(1,1-dimethylethyl)-4-(phenylmethoxy)phenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204000-62-4 CAPLUS

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Morpholine, 4-[[[3-[[[3-bromo-5-(1,1-dimethylethyl)-4-methoxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 204000-63-5 CAPLUS
CN Morpholine, 4-[[[3-[[[3-bromo-5-(1,1-dimethylethyl)-4-(phenylmethoxy)phenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



IT 204000-64-6P, 3-(3-tert-Butyl-5-chloro-4-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204000-65-7P,

3-(4-(Benzoyloxy)-5-tert-butyl-3-chlorobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204000-66-8P, 3-(3-tert-Butyl-5-iodo-4-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204001-07-0P, 3-(4-(Benzoyloxy)-3-tert-butyl-5-iodobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-08-1P,

3-(3-tert-Butyl-4-methoxy-5-nitrobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-09-2P, 3-(3,5-Di-tert-butyl-4-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-10-5P, 3-(4-(Benzoyloxy)-3,5-di-tert-butylbenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-11-6P, 3-(3,5-Dimethyl-4-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-12-7P, 3-(4-(Benzoyloxy)-3,5-dimethylbenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-13-8P, 3-(5-Bromo-2-hydroxy-3-methoxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-14-9P,

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
3-(5-Bromo-2-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-15-0P, 3-(2-Hydroxy-5-nitrobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-16-1P, 3-(4-Hydroxy-3-methoxy-2-nitrobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-17-2P, 3-(4-(Benzoyloxy)-3-tert-butyl-5-iodobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-18-3P, 3-(3-tert-Butyl-4-methoxy-5-nitrobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-19-4P, 3-(3,5-Di-tert-butyl-4-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-20-5P, 3-(4-(Benzoyloxy)-3,5-di-tert-butylbenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-21-6P, 3-(4-(Benzoyloxy)-3,5-di-tert-butylbenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-22-7P, 3-(3,5-Dimethyl-4-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-23-0P, 3-(4-(Benzoyloxy)-3,5-dimethylbenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-24-1P, 3-(5-Bromo-2-hydroxy-3-methoxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-25-2P, 3-(5-Bromo-2-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-26-3P, 3-(2-Hydroxy-5-nitrobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-27-4P, 3-(4-Hydroxy-3-methoxy-2-nitrobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-28-5P, 3-(4-(Benzoyloxy)-3-tert-butyl-5-iodobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204001-29-6P, 3-(3-tert-Butyl-4-methoxy-5-nitrobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204001-30-7P, 3-(3,5-Di-tert-butyl-4-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204001-31-0P, 3-(4-(Benzoyloxy)-3,5-di-tert-butylbenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204001-32-1P, 3-(3,5-Dimethyl-4-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204001-33-2P, 3-(4-(Benzoyloxy)-3,5-dimethylbenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204001-34-3P, 3-(5-Bromo-2-hydroxy-3-methoxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204001-35-4P, 3-(5-Bromo-2-hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204001-36-5P, 3-(2-Hydroxy-5-nitrobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204001-37-6P, 3-(4-Hydroxy-3-methoxy-2-nitrobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204001-38-7P, 3-(3-Ethoxy-2-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-39-8P, 3-(3,5-Dichloro-2-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-40-9P, 3-(5-Chloro-2-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-41-0P, 3-(4-(Diethylamino)-2-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-42-1P, 3-(4-Nitrobenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-43-2P, 3-(3,5-Dibromo-2-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-44-3P, 3-(3-Fluoro-2-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-45-4P, 3-(3-Bromo-4-hydroxybenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-46-5P, 3-(4-tert-Butylbenzylidenyl)-5-[(methylamino)sulfonyl]-2-indolinone 204001-47-6P, 3-[(2-Bromothien-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 204001-48-7P, 3-(3-Ethoxy-2-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-49-8P,

Kamal Saeed

10141236

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)

lfonyl]-2-indolinone 204001-89-8P, 3-(3,5-Dichloro-2-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-90-1P, 3-(5-Chloro-2-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-91-2P, 3-[4-(Diethylamino)-2-hydroxybenzylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-92-3P

3-(4-Nitrobenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-93-4P, 3-(3,5-Dibromo-2-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-94-5P, 3-(3-Fluoro-2-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-95-6P

3-(3-Bromo-4-hydroxybenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-96-7P, 3-(4-tert-Butylbenzylidenyl)-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-97-8P, 3-[[2-Bromothien-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 204001-98-9P, 3-(3-Ethoxy-2-hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204001-99-0P, 3-(3,5-Dichloro-2-hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204002-00-6P, 3-(5-Chloro-2-hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204002-01-7P, 3-[4-(Diethylamino)-2-hydroxybenzylidenyl]-5-(morpholinosulfonyl)-2-indolinone 204002-02-8P, 3-(4-Nitrobenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204002-03-9P, 3-(3,5-Dibromo-2-hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204002-04-0P, 3-(3-Fluoro-2-hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204002-05-1P, 3-(3-Bromo-4-hydroxybenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204002-06-2P, 3-(4-tert-Butylbenzylidenyl)-5-(morpholinosulfonyl)-2-indolinone 204002-07-3P, 3-[[2-Bromothien-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and testing of indolinone combinatorial library as protein kinase inhibitors)


RN 204000-64-6 CAPLUS

CN Morpholine, 4-[[3-[[3-chloro-5-(1,1-dimethylethyl)-4-methoxyphenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 204001-07-0 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[3-[[3-(1,1-dimethylethyl)-5-iodo-4-(phenylmethoxy)phenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-08-1 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[3-[[3-(1,1-dimethylethyl)-4-methoxy-5-nitrophenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 204001-09-2 CAPLUS


CN 1H-Indole-5-sulfonamide, 3-[[3,5-bis(1,1-dimethylethyl)-4-methoxyphenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 204001-10-5 CAPLUS


CN 1H-Indole-5-sulfonamide, 3-[[3,5-bis(1,1-dimethylethyl)-4-(phenylmethoxy)phenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204000-65-7 CAPLUS


CN Morpholine, 4-[[3-[[3-chloro-5-(1,1-dimethylethyl)-4-(phenylmethoxy)phenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 204000-66-8 CAPLUS


CN Morpholine, 4-[[3-[[3-(1,1-dimethylethyl)-5-iodo-4-methoxyphenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 204001-11-6 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[[4-methoxy-3,5-dimethylphenyl]methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-12-7 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[3,5-dimethyl-4-(phenylmethoxy)phenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 204001-13-8 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[5-bromo-2-hydroxy-3-methoxyphenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-14-9 CAPLUS


Kamal Saeed

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 1H-Indole-5-sulfonamide, 3-[(5-bromo-2-hydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 204001-15-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-hydroxy-5-nitrophenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-16-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-hydroxy-3-methoxy-2-nitrophenyl)methylene]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-17-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-[(1,1-dimethylethyl)-5-iodo-4-(phenylmethoxy)phenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 204001-21-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-bis(1,1-dimethylethyl)-4-(phenylmethoxy)phenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204001-22-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(4-methoxy-3,5-dimethylphenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204001-23-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dimethyl-4-(phenylmethoxy)phenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 204001-18-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-[(1,1-dimethylethyl)-4-methoxy-5-nitrophenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204001-19-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-bis(1,1-dimethylethyl)-4-methoxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204001-24-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(5-bromo-2-hydroxy-3-methoxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204001-25-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(5-bromo-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204001-26-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-[(2-hydroxy-5-nitrophenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 204001-27-4 CAPLUS
CN 1H-indole-5-sulfonamide, 2,3-dihydro-3-[(4-hydroxy-3-methoxy-2-nitrophenyl)methylene]-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204001-28-5 CAPLUS
CN Morpholine, 4-[[3-[[3-(1,1-dimethylethyl)-5-iodo-4-(phenylmethoxy)phenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204001-32-1 CAPLUS
CN Morpholine, 4-[[3-[[3-(1,1-dimethylethyl)-5-iodo-4-(phenylmethoxy)phenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204001-33-2 CAPLUS
CN Morpholine, 4-[[3-[[3-(1,1-dimethylethyl)-5-iodo-4-(phenylmethoxy)phenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204001-34-3 CAPLUS
CN Morpholine, 4-[[3-[[3-(1,1-dimethylethyl)-5-iodo-4-(phenylmethoxy)phenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 204001-29-6 CAPLUS
CN Morpholine, 4-[[3-[[3-(1,1-dimethylethyl)-4-methoxy-5-nitrophenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204001-30-9 CAPLUS
CN Morpholine, 4-[[3-[[3-bis(1,1-dimethylethyl)-4-methoxyphenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204001-31-0 CAPLUS
CN Morpholine, 4-[[3-[[3-bis(1,1-dimethylethyl)-4-(phenylmethoxy)phenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204001-35-4 CAPLUS
CN Morpholine, 4-[[3-[[3-bis(1,1-dimethylethyl)-4-methoxyphenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204001-36-5 CAPLUS
CN Morpholine, 4-[[3-[[3-bis(1,1-dimethylethyl)-4-methoxyphenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204001-37-6 CAPLUS
CN Morpholine, 4-[[3-[[3-bis(1,1-dimethylethyl)-4-methoxyphenyl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204001-78-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-ethoxy-2-hydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-79-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dichloro-2-hydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-80-9 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(5-chloro-2-hydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 204001-81-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-(diethylamino)-2-hydroxyphenyl]methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 204001-82-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-nitrophenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-83-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dibromo-2-hydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 204001-84-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-fluoro-2-hydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-85-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-bromo-4-hydroxyphenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 204001-86-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-(1,1-dimethylethyl)phenyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-87-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(5-bromo-2-thienyl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 204001-88-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3-ethoxy-2-hydroxyphenyl)methylene]-2,3-


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 204001-89-8 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(3,5-dichloro-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 204001-90-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(5-chloro-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204001-91-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-(diethylamino)-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Kamal Saeed

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204001-92-3 CAPLUS
CN 1H-Indole-5-sulfonamide,
2,3-dihydro-3-[[4-(trifluoromethyl)phenyl]methylene]-2-oxo-N-
[(4-(trifluoromethyl)phenyl)methylene]- (9CI) (CA INDEX NAME)




RN 204001-93-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(5-dibromo-2-hydroxyphenyl)methylene]methylene]-2,3-
dihydro-2-oxo-N-[(4-(trifluoromethyl)phenyl)methylene]- (9CI) (CA INDEX NAME)




RN 204001-94-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(3-fluoro-2-hydroxyphenyl)methylene]methylene]-2,3-
dihydro-2-oxo-N-[(4-(trifluoromethyl)phenyl)methylene]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 1H-Indole-5-sulfonamide, 3-[[5-bromo-2-thienyl)methylene]methylene]-2,3-dihydro-2-
oxo-N-[(4-(trifluoromethyl)phenyl)methylene]- (9CI) (CA INDEX NAME)



RN 204001-98-9 CAPLUS
CN Morpholine,
4-[[3-[[3-(3-ethoxy-2-hydroxyphenyl)methylene]methylene]-2,3-dihydro-2-oxo-
1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204001-99-0 CAPLUS
CN Morpholine,
4-[[3-[[3-(3,5-dichloro-2-hydroxyphenyl)methylene]methylene]-2,3-dihydro-2-oxo-
1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204002-00-6 CAPLUS
CN Morpholine,
4-[[3-[[3-(5-chloro-2-hydroxyphenyl)methylene]methylene]-2,3-dihydro-2-oxo-
1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
dihydro-2-oxo-N-[(4-(trifluoromethyl)phenyl)methylene]- (9CI) (CA INDEX NAME)



RN 204001-95-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[3-(3-bromo-4-hydroxyphenyl)methylene]methylene]-2,3-
dihydro-2-oxo-N-[(4-(trifluoromethyl)phenyl)methylene]- (9CI) (CA INDEX NAME)




RN 204001-96-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-(1,1-dimethylethyl)phenyl)methylene]methylene]-2,3-
dihydro-2-oxo-N-[(4-(trifluoromethyl)phenyl)methylene]- (9CI) (CA INDEX NAME)




RN 204001-97-8 CAPLUS


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204002-01-7 CAPLUS
CN Morpholine, 4-[[3-[[4-(diethylamino)-2-hydroxyphenyl)methylene]methylene]-2,3-
dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 204002-02-8 CAPLUS
CN Morpholine,
4-[[2,3-dihydro-3-[[4-(nitrophenyl)methylene]methylene]-2-oxo-1H-indol-5-
yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 204002-03-9 CAPLUS
CN Morpholine, 4-[[3-[[3-(3,5-dibromo-2-hydroxyphenyl)methylene]methylene]-2,3-dihydro-2-
oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

Kamal Saeed

10141236


L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 204002-04-0 CAPLUS


CN Morpholine,

4-[[3-[(3-fluoro-2-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 204002-05-1 CAPLUS

CN Morpholine, 4-[[3-[(3-bromo-4-hydroxyphenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 204002-06-2 CAPLUS

CN Morpholine, 4-[[3-[(4-(1,1-dimethylethyl)phenyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:577724 CAPLUS

DOCUMENT NUMBER: 125:221574

TITLE: Preparation of hydrosoluble 3-arylidene-2-oxindole tyrosine Kinase inhibitors

INVENTOR(S): Buzzetti, Franco; Brasco, Maria Gabriella; Longo, Antonio; Ballinari, Dario

PATENT ASSIGNEE(S): Pharmacia S.P.A., Italy

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9622976	A1	19960801	WO 1995-EP5176	19951222
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2186508	AA	19960801	CA 1995-2186508	19951222
AU 9644363	A1	19960814	AU 1996-44363	19951222
AU 697673	B2	19981015		
EP 752985	A1	19970115	EP 1995-943238	19951222
EP 752985	B1	19990804		
R: CH, DE, ES, FR, GB, IT, LI, SE				
JP 09510993	T2	19971104	JP 1995-522571	19951222
ES 2137562	T3	19991216	ES 1995-943238	19951222
IL 116851	A1	20000601	IL 1996-116851	19960122
US 5840745	A	19981124	US 1996-704760	19960925
PRIORITY APPLN. INFO.:				
GB 1995-1567 A 19950126				
WO 1995-EP5176 W 19951222				

OTHER SOURCE(S): MARPAT 125:221574

GI For diagram(s), see printed CA Issue.

AB 3-Arylidene-2-oxindole derivs. [I; m = 0-2; A = (un)substituted bicyclic ring chosen from tetralin, naphthalene, quinoline and indole; R1 = H, alkyl, alkanoyl; one of R2 and R3 is H and the other is (un)substituted alkyl, (un)substituted alkoxy, carbonyl, (un)substituted SO3H, (CH2)n(alkyl)2, etc.; n = 2, 3], useful as tyrosine kinase inhibitors

for the treatment of tumors, diabetic complications (no data), restenosis (no data), etc. (no data), are prepd. and 1-contg. formulations presented. Thus, 3-carbethoxy-3-(5-methoxyindol-3-ylmethylene)-2-oxindole was prepd. and demonstrated a IC50 of 1.99 .mu.M against v-abl tyrosine kinase and a IC50 of 2.34 .mu.M against the growth of K562 chronic myeloid leukemia cells.

IT 181222-46-8P 181222-86-6P 181222-88-8P

181222-90-2P 181222-07-4P 181222-16-5P

181222-65-4P


RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of hydrosol. 3-arylidene-2-oxindole tyrosine kinase inhibitors)

RN 181222-46-8 CAPLUS


CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(1,2,3,4-tetrahydro-3-hydroxy-2-naphthalenyl)methylene]- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 204002-07-3 CAPLUS

CN Morpholine, 4-[[3-[(5-bromo-2-thienyl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 181222-86-6 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(1,2,3,4-tetrahydro-1,4-dihydroxy-2-naphthalenyl)methylene]- (9CI) (CA INDEX NAME)




RN 181222-88-8 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(1,2,3,4-tetrahydro-1,4-dihydroxy-2-naphthalenyl)methylene]- (9CI) (CA INDEX NAME)



RN 181222-90-2 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(1,2,3,4-tetrahydro-1,4-dihydroxy-2-naphthalenyl)methylene]- (9CI) (CA INDEX NAME)




RN 181222-07-4 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(4-quinolinyl)methylene]- (9CI) (CA INDEX NAME)


Kamal Saeed

10141236


L4 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 181223-16-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo- (9CI) (CA INDEX NAME)




RN 181223-65-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(2-naphthalenylmethylene)-2-oxo- (9CI) (CA INDEX NAME)




L4 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
IT 175075-26-0P 175075-98-6P 175075-99-7P 175076-00-3P 175076-01-4P 175076-02-5P 175076-03-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of substituted azaindolylidene compds. as tyrosine kinase inhibitors)

RN 175075-26-0 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)- (9CI) (CA INDEX NAME)




RN 175075-98-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 175075-99-7 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:20965 CAPLUS
DOCUMENT NUMBER: 124:260834
TITLE: Preparation and formulation of substituted azaindolylidene compounds as tyrosine kinase inhibitors
INVENTOR(S): Buzzetti, Franco; Brasca, Gabriella Maria; Longo, Antonio; Ballinari, Dario
PATENT ASSIGNEE(S): Pharmacia S.P.A., Italy
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9600226	A1	19960104	WO 1995-EP2043	19950530
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, DE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2168659	AA	19960104	CA 1995-2168659	19950530
AU 9526716	A1	19960119	AU 1995-26716	19950530
EP 715628	A1	19960612	EP 1995-921777	19950530
EP 715628	B1	20021002		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
CN 1129941	A	19960828	CN 1995-190567	19950530
HU 74609	A2	19970128	HU 1996-729	19950530
JP 09502457	T2	19970311	JP 1995-502741	19950530
AT 225348	E	20021015	AT 1995-921777	19950530
ZA 9505223	A	19960131	ZA 1995-5223	19950623
US 5663346	A	19970902	US 1996-592297	19960209
FI 9600751	A	19960219	FI 1996-751	19960219
NO 9600713	A	19960222	NO 1996-713	19960222
PRIORITY APPLN. INFO.:			GB 1994-12719	A 19940624
			WO 1995-EP2043	W 19950530
OTHER SOURCE(S):		MARPAT 124:260834		
GI				



AB The title compds. I [one of X1, X2, X3, X4 is N and the others are CH; R is CH:(CN)CONH2, etc.; R1 is hydrogen, amino, carboxy, cyano, etc.; R2 is H, C1-C6 alkyl, etc.; a proviso is given] are prepd. 5-Cyano-3-((7-


L4 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 175076-00-3 CAPLUS
CN Piperazine, 1-[[2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl]sulfonyl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 175076-01-4 CAPLUS
CN Piperazine, 1-[[2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl]sulfonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 175076-02-5 CAPLUS
CN 1-Piperazineethanol, 4-[[2,3-dihydro-3-(1H-indol-3-ylmethylene)-2-oxo-1H-indol-5-yl]sulfonyl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 175076-03-6 CAPLUS
CN 1-Piperazineethanol, 4-[[2,3-dihydro-2-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-1H-indol-5-yl]sulfonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10141236

L4 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)




L4 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:931240 CAPLUS
 DOCUMENT NUMBER: 123:339727
 TITLE: Preparation of substituted indolone phosphodiesterase-IV inhibitors
 INVENTOR(S): Maamune, Hiroko
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9514667	A1	19950601	WO 1994-1B312	19941012
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5502072	A	19960326	US 1993-164973	19931126
CA 2176506	AA	19950601	CA 1994-2176506	19941012
CA 2176506	C	19980623		
CA 2224049	AA	19950601	CA 1994-2224049	19941012
CA 2224051	AA	19950601	CA 1994-2224051	19941012
EP 730579	A1	19960911	EP 1994-927777	19941012
EP 730579	B1	20010307		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09500145	T2	19970107	JP 1994-514931	19941012
JP 2747116	B2	19980506		
AT 199544	E	20010315	AT 1994-927777	19941012
ES 2154683	T3	20010416	ES 1994-927777	19941012
FI 9405555	A	19950527	FI 1994-5555	19941125
JP 10182606	A2	19980707	JP 1997-285483	19971017
JP 3106118	B2	20001106		
PRIORITY APPLN. INFO.:				
			US 1993-164973	A1 19931126
			JP 1995-514931	A3 19941012
			WO 1994-1B312	W 19941012
OTHER SOURCE(S): MARPAT 123:339727				
GI				

L4 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



AB The title compds. [I; R1 = alkyl, phenylalkyl; R2 = alkyl, phenylalkyl, cycloalkyl, polycycloalkyl; R3 = H, alkyl, alkoxy, carbonyl, (un)substituted CONH2, etc.; R5, R6, R7 = H, halogen, alkoxy, cycloalkoxy, NO2, acyloxy, etc.; R9 = H, alkyl; X = N, (un)substituted CH; the dotted line represents an optional double bond], useful as phosphodiesterase-IV inhibitors (no data) in the treatment of AIDS (no data), asthma (no data), rheumatoid arthritis (no data), osteoarthritis (no data), bronchitis (no data), chronic-obstructive airway disease (no data), etc., are prepd. Thus, indolone II E-isomer (m.p. 204-205.degree.) was prepd.


IT 170566-12-8P 170717-61-0P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of substituted indolone phosphodiesterase-IV inhibitors)

RN 170566-12-8 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[3-(bicyclo[2.2.1]hept-2-yloxy)-4-methoxyphenyl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo-, [1.alpha.,2.alpha.(E),4.alpha.]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.


L4 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 170717-61-0 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[3-(bicyclo[2.2.1]hept-2-yloxy)-4-methoxyphenyl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo-, [1.alpha.,2.alpha.(Z),4.alpha.]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



10141236

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

101.46

251.02

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-14.32

-14.32

STN INTERNATIONAL LOGOFF AT 08:29:21 ON 14 JAN 2003